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Controlled Degradation And Release For Cardiac Repair
Abstract
Guest-host chemistry is an emerging tool in the preparation of biomaterials. Towards the design of hydrogels,
guest-host chemistry has been used to impart unique shear-thinning and self-healing properties that allow
these materials to be injected through syringes and catheters as a single component, avoiding complications
associated with traditional covalent systems. As a treatment for myocardial infarction, injectable guest-host
hydrogels may be injected directly into the myocardial wall and have shown therapeutic benefit in a number of
strategies, including drug delivery, cell delivery, and tissue bulking. As delivery systems, injectable hydrogels
provide controlled release of payloads that attenuate maladaptive remodeling of the left ventricle, by inhibiting
expression of proteases, recruiting cells to the region, or otherwise stimulating therapeutic biological
processes such as angiogenesis. Guest-host biomaterials must be refined and advanced to overcome challenges
associated with delivering therapeutics in these areas, as well as to provide novel materials platforms for
investigating therapeutic delivery in the future. This dissertation describes the engineering of two injectable
hydrogel platforms that address challenges in the delivery of therapeutics after myocardial infarction. Each of
these systems is investigated both in vitro for an understanding of material properties and the parameters that
tune them, as well as in vivo, in a number of clinically relevant animal models and therapeutic targets. In the
first aim of this thesis, isotropic guest-host hydrogels are designed for the sustained release of a variety of small
molecules. Through the control of small molecule binding with cyclodextrin host moieties engineered in the
hydrogel, we show that both cyclodextrin content and molecule affinity for cyclodextrin are critical factors
that provide tunable release of small molecules from these systems. Furthermore, we demonstrate that this
system is broadly applicable to the release of a number of pharmaceutical small molecule payloads. In the
second aim of this thesis, isotropic guest-host hydrogels are specifically formulated for the delivery of the
small molecule protease inhibitor SD-7300, a therapeutic requiring local delivery after myocardial infarction.
Here we demonstrate that the engineered guest-host hydrogels provide sustained release and retain activity of
this molecule, which in turn provides improved functional and biological outcomes in a large-animal model of
myocardial infarction. In the third aim of this thesis, guest-host chemistry is utilized to assemble
microstructured granular hydrogels for the design of multifunctional material platforms. Granular hydrogels
are demonstrated to have disease responsivity in myocardial infarction, and functional benefit through the
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GUEST-HOST INTERACTIONS TO ENGINEER INJECTABLE HYDROGELS WITH 
CONTROLLED DEGRADATION AND RELEASE FOR CARDIAC REPAIR 
Joshua E. Mealy 
Jason A. Burdick, Ph.D. 
Guest-host chemistry is an emerging tool in the preparation of biomaterials. 
Towards the design of hydrogels, guest-host chemistry has been used to impart unique 
shear-thinning and self-healing properties that allow these materials to be injected 
through syringes and catheters as a single component, avoiding complications 
associated with traditional covalent systems. As a treatment for myocardial infarction, 
injectable guest-host hydrogels may be injected directly into the myocardial wall and 
have shown therapeutic benefit in a number of strategies, including drug delivery, cell 
delivery, and tissue bulking. As delivery systems, injectable hydrogels provide controlled 
release of payloads that attenuate maladaptive remodeling of the left ventricle, by 
inhibiting expression of proteases, recruiting cells to the region, or otherwise stimulating 
therapeutic biological processes such as angiogenesis. Guest-host biomaterials must be 
refined and advanced to overcome challenges associated with delivering therapeutics in 
these areas, as well as to provide novel materials platforms for investigating therapeutic 
delivery in the future.  
This dissertation describes the engineering of two injectable hydrogel platforms 
that address challenges in the delivery of therapeutics after myocardial infarction. Each 
of these systems is investigated both in vitro for an understanding of material properties 
and the parameters that tune them, as well as in vivo, in a number of clinically relevant 
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animal models and therapeutic targets. 
In the first aim of this thesis, isotropic guest-host hydrogels are designed for the 
sustained release of a variety of small molecules. Through the control of small molecule 
binding with cyclodextrin host moieties engineered in the hydrogel, we show that both 
cyclodextrin content and molecule affinity for cyclodextrin are critical factors that provide 
tunable release of small molecules from these systems. Furthermore, we demonstrate 
that this system is broadly applicable to the release of a number of pharmaceutical small 
molecule payloads.  
In the second aim of this thesis, isotropic guest-host hydrogels are specifically 
formulated for the delivery of the small molecule protease inhibitor SD-7300, a 
therapeutic requiring local delivery after myocardial infarction. Here we demonstrate that 
the engineered guest-host hydrogels provide sustained release and retain activity of this 
molecule, which in turn provides improved functional and biological outcomes in a large-
animal model of myocardial infarction. 
In the third aim of this thesis, guest-host chemistry is utilized to assemble 
microstructured granular hydrogels for the design of multifunctional material platforms. 
Granular hydrogels are demonstrated to have disease responsivity in myocardial 
infarction, and functional benefit through the delivery of the chemokine SDF-1α.  
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Cardiovascular disease accounts for 17.3 million deaths annually and is the 
leading cause of death across the globe; within cardiovascular diseases, ischemic heart 
disease is the most deadly.1,2 Specifically, almost one in four deaths in the United 
States, or 610,000 individuals die every year of heart disease.3 Myocardial infarction (MI) 
is among the most prominent and lethal types of heart disease, affecting 735,000 
Americans annually. MI occurs after an occlusion of the coronary artery disrupts the 
normal perfusion of the myocardium (Figure 1.1). This ischemic event leads to cell 
necrosis and inflammation, including the loss of cardiomyocytes - the contractile cell of 
the heart.  
 	  	  
Figure 1.1. Schematic representation of myocardial infarction. Plaque buildup within 
a coronary artery ruptures, leading to thrombus formation and occlusion of the vessel. 
Ischemia as a result of this occlusion leads to muscle damage in the myocardial tissue. 
Adapted from Bax et al.4 
 
As an immediate treatment, interventions are focused on restoring blood flow (i.e. 
repurfusion) to the myocardium through biochemical approaches such as fibrinolytics or 
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thrombolytics, or through minimally invasive surgical approaches such as coronary 
angioplasty.5 In the case of damage to the coronary arteries, blood flow may be restored 
through bypass surgery.6 These treatments are effective in improving the initial patient 
survival after infarction; however, they fail to address the long-term biological and 
structural changes that occur with MI. Ultimately, many patients with an MI proceed to 
develop heart failure in the long-term, with nearly a 50% mortality rate at 5 years after 
hospitalization.1  
Managing heart failure currently involves pharmacologic interventions to increase 
blood flow to the myocardium and to reduce stress on the heart by reducing heart rate 
and blood pressure (beta blockers and ACE inhibitors).5 Currently, the only way to return 
to stable, healthy cardiac function in those with end-stage heart failure is through 
transplant, where donor hearts are very limited.7 Mechanical interventions such as left 
ventricular assist devices (LVADs) provide a temporary solution to induce systemic 
blood flow; however, LVADs are not currently seen as a permanent solution for patients 
with heart failure.8,9 Collectively, while these treatments are effective in mitigating the 
issues associated with heart failure after MI, they fail to directly address the underlying 
biological processes involved early on in the progression of the disease.  
 
1.2. DISEASE PROGRESSION AND LEFT VENTRICULAR REMODELING AFTER MI 
The initial ischemic event that leads to MI is followed by a three-phase wound 
healing response consisting of inflammatory, proliferative, and maturation phases 
(Figure 1.2).10 During the inflammatory phase, monocytes infiltrate the infarct region and 
differentiate into macrophages, which serve to phagocytose cellular debris, secrete a 
variety of inflammatory proteins, and stimulate fibroblasts towards the secretion of 
proteases, which degrade the local environment. These protease levels remain elevated, 
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and along with a concurrent decrease in the endogenous inhibitors (tissue inhibitors of 
metalloproteinases, TIMPs), contribute to an overall increase in proteolytic activity and a 
general loss of integrity of the extracellular matrix in the infarcted myocardium.11-14 
During the proliferative phase, fibroblasts begin to deposit fibrous tissue and in the 
maturation phase, matrix crosslinking and further apoptosis of myofibroblasts leads to 
the formation of a fibrous scar. Generally, the beginning of cardiomyocyte death and the 
inflammatory phase commences within hours of the initial infarct, and can last for several 
days to a week after infarction. The proliferation of myofibroblasts follows, as well as the 
upregulation of protease activity and can last for several weeks. Finally, in the following 
weeks to months after these phases, scar tissue matures.10 While these phases give a 
general outline of the biological changes after MI, they are not necessarily sequential, as 
things such as protease activity and cardiomyocyte death are progressive with time, and 





Figure 1.2. Phases of wound healing after myocardial infarction and their 
underlying biological processes. The initial ischemic event as part of myocardial 
infarction is followed by three distinct phases with unique underlying biological 
processes. During the inflammatory phase, cardiomyocytes undergo apoptosis and 
necrosis, leading to an immediate loss of the functional cell type in the infarcted region. 
This is followed by an invasion of neutrophils and monocytes that directly and indirectly 
contribute to an elevation in MMP activity, phagocytosis, and general degradation of the 
extracellular matrix. This phase is followed by a proliferative phase during which 
fibroblasts differentiate into myofibroblasts and commence production of collagenous 
matrix, while endothelial cells contribute to angiogenesis and the production of new 
vessels. Finally, in the maturation phase, matrix is crosslinked into a dense collagenous 
scar. Adapted from Matsui et al. 10 
 
Concomitant with these biological changes, global changes occur in the left 
ventricle (LV) known as left ventricular remodeling.15 During LV remodeling, the LV 
transitions to a dilated state, which includes expansion of the initial infarct region and 
thinning of the myocardial wall (Figure 1.3).12,15 These changes result in a loss of 
pumping efficiency in the heart and ultimately contribute to the progression of long-term 
heart failure and mortality.12,15,16 
The elevation of matrix metalloproteinases (MMPs) and subsequent loss of 
matrix mechanics has largely been implicated in LV remodeling.11-14,16-19 These 
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proteinases are secreted by a variety of cells, including endogenous cardiac fibroblasts 
and cardiomyocytes as well as invading cells mobilizing as part of the inflammatory 
response. Of key importance after MI, are MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, 
MMP-9, and MMP-14, which have been shown to increase after MI.20 This activity often 
persists long after the development of an infarction (Figure 1.4). Directly, this family of 
proteins is responsible for degradation of highly specific peptide sequences in the ECM. 
This proteolytic activity alters a number of downstream processes in the infarcted 
myocardium, including tissue mechanics, inflammation, cell invasion, and even direct 
feed-forward regulation of other subtypes of MMPs.20,21 Ultimately, elevation of MMPs 
has been correlated with a loss of function in the myocardium.  
 
Figure 1.3. Ventricular remodeling after acute MI. After initial infarction, the portion of 
the myocardium affected by the infarct begins to expand during the initial hours to days. 
Within days to months, there is global remodeling in the LV that leads to a decrease in 
systolic function, ventricular dilation, and thinning of the myocardial wall, all of which 
contribute to the progression of long term heart failure. Adapted from Jessup et al.23 
 
In addition to the elevation of proteinases after MI, a subsequent down-regulation 
of their endogenous inhibitors, TIMPs, also contributes to the net effect of this proteolytic 
activity. Because of the disruption of this balance, experimental interventions restoring 
MMP inhibitory action in the myocardium through the delivery of exogenous inhibitors 
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have proven effective in improving functional outcomes.19,22 Indeed, it has even been 
hypothesized that currently administered clinical therapeutics may have partial benefit 
due to their influence on MMP activity and regulation in the myocardium.20  
 
 
Figure 1.4. Relative activity of MMP subtypes and TIMP subtypes in various 
regions of the myocardium. Analyzed at 8 weeks after infarction in an ovine model of 
MI, researchers observed an elevation of MMP activity most strongly in the infarct region 
in the MMP-2, MMP-8, MMP-13, and MT1-MMP subtypes. This was coupled with a 
relative decrease in TIMP-1,-2, and -3 subtypes in the infarct region. Adapted from 
Wilson et al.11  
  
 
Ultimately, this collection of maladaptive changes presents a number of crucial 
barriers that prohibit the healing of the myocardium and a return to the pre-MI healthy 
tissue state. First, an acute loss of matrix integrity contributes to infarct expansion and 
global LV remodeling. Furthermore, necrosis of cardiomyocytes provides an irreversible 
loss in contractility, as these cells have little innate regenerative capacity. Finally, in the 
long term, the infarcted tissue transitions to a collagen-dense non-contractile tissue with 
little vascularization. Despite these challenges, understanding of the remodeling 
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processes can help guide new patient therapies.  For example, blocking of early 
increases in MMP activity to salvage matrix mechanics or regenerative approaches 
revascularizing or inducing cardiomyocyte proliferation in the infarct may improve clinical 
outcomes. Often, these approaches require localization to the myocardium, and are 
facilitated through the use of biomaterials.  
 
1.3. HYDROGELS IN CARDIAC REMODELING 
Biomaterials have recently become a strategy to address the barriers to recovery 
that are faced after an infarction.24 Initially, mechanical restriction of the left ventricle 
using epicardial wraps was shown to be effective in attenuating LV dilation and infarct 
expansion.25-27 These studies were followed by the use of commercially available dermal 
fillers as direct injections into the myocardial wall, which were also successful in 
attenuating LV remodeling and promoting improved functional outcomes.28  
In addition to polymeric meshes, hydrogels have also been used as therapies to 
the heart after MI. Hydrogels are water-swollen polymer networks that can be made from 
synthetic or natural polymers, and are cross-linked in either covalent or non-covalent 
manners. Early work investigating the utility of hydrogels in the myocardium began with 
Christman et al and the use of fibrin glues.29 This field has evolved and numerous types 
of hydrogels have now been investigated after MI.24 Synthetic materials such as 
pNIPAAM and PEG have been explored, as well as a wide range of natural materials 
including alginate, collagen, chitosan, hyaluronic acid, as well as extracellular matrix 
products.30-38 These materials have been crosslinked utilizing a variety of mechanisms, 
including covalent mechanisms, thermo-responsive gelation, ionic crosslinking, 
enzymatic crosslinking, as well as self-assembly. Hydrogels are most commonly 
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delivered directly into the myocardial wall, which has been done through direct epicardial 
intramuscular injections, as well as intra-coronary and endocardial approaches.  
Recently, these approaches have resulted in the formation of several products in 
early phase clinical trials. VentriGel, a product of Ventrix, is a porcine ECM product that 
is delivered via an endocardial catheter based approach and is in Phase 1 clinical trials 
(NCT02305602). Algisyl, a product of LoneStar Heart Inc., is an alginate product that is 
directly injected into the myocardium. Algisyl has shown efficacy in improving aerobic 
capacity of patients presenting heart failure, where hydrogel injections are applied 
concurrently with other standard treatment procedures such as valve replacement or 
bypass grafts.39,40 In short, hydrogels have developed into a robust tool to address LV 
remodeling that is beginning to see clinical translation. 
Mechanistically, these pre-clinical and clinical hydrogels are thought to impact 
remodeling by altering the mechanical forces experienced by the heart through bulking 
the myocardial wall.24 The law of Laplace states that the wall stress experienced by the 
LV is inversely proportional to the thickness of the myocardial wall. By increasing the 
wall thickness with hydrogel injections, wall stress can be reduced (Figure 1.5). Both 
modeling and empirical approaches have shown the effect of alterations in injection 
volume and material mechanics on the mechanical forces acting on the myocardium.37,41 
While it is likely that the functional improvements observed are a result of direct 
mechanical alterations in the myocardium, a number of biological pathways persist that 
are not targeted by hydrogel mechanics alone. For example, biomaterials through their 
innate or designed inflammatory response may lead to alterations in local collagen 
production that can act to stabilize the tissue. 
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Figure 1.5. Finite element model of hydrogel injection into the myocardial wall. 
Nine injection sites of 150 µL hydrogel volumes at 0.1 kPa (a), 25 kPa (b), and 100 kPa 
(c) or using 300 µL volumes at 0.1 kPa (d), 25 kPa (e), and 100 kPa (f). Myocardial wall 
stress (represented by the colorimetric scale) is reduced proportionally to hydrogel 
stiffness and volume of injection. Adapted from Wang et al. 41  
 
In addition to providing mechanical intervention, hydrogels have the capacity to 
provide numerous other therapeutic strategies in MI. As lack of innate cellular 
regeneration is a significant barrier to restoration of normal function in the myocardium, 
cellular delivery is one approach to improving cardiac function. Numerous clinical trials 
have been investigated on the delivery of a variety of cell types (bone marrow derived 
stem cells, mesenchymal stem cells, endothelial progenitor cells, and cardiac stem cells) 
to the myocardium.42 Clinical efficacy of these trials has been mixed and have largely 
been dependent on both cell lineage, viability, and retention in the myocardium. 
 As direct injections of cells alone often result in significant cell death, hydrogels 
have been designed as carriers for a variety of cell types to optimize cell viability, 
retention, and cell-material interactions at the injection site.29,43,44 While these strategies 
have been effective, it is often difficult to pinpoint mechanistically the effect of cell 
delivery as their interactions are often complex. Additionally, logistical concerns of cell 
source and quality are often a concern when translating these therapies.  
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1.4. HYDROGELS FOR DRUG DELIVERY IN THE MYOCARDIUM 
Towards more controlled biological interventions, hydrogels have also been used 
as drug delivery vehicles for a wide variety of payloads. From a design perspective, 
hydrogels have numerous features that can be tailored to influence drug release across 
a range of size scales (Figure 1.6). At the largest scale, hydrogel size can influence 
drug release, as smaller sizes and increasing surface area contact with the environment 
will lead to more rapid release.45 At the meso scale, hydrogels can be designed as either 
non-porous materials or to be macroporous, with an increasing porosity often associated 
with more rapid drug release.45 
 
Figure 1.6. Overview of hydrogel design parameters influencing drug release. 
Hydrogel size, porosity, mesh-size, and chemical linkers all contribute to the controlled 
release of encapsulate payloads. Adapted from Li et al. 45 
 
At the micro- and nano-scales, hydrogel mesh size is also a key influencer of 
drug release properties. This property may be influenced through a variety of factors 
including polymer concentration, crosslinking density, and crosslinker degradability 
(Figure 1.7).45 This mesh size can be largely static, or increase through hydrogel 
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swelling and degradation (Figure 1.7). Furthermore, the relative relationship of mesh 
size to drug size also contributes to release behavior of drugs from hydrogels, with 
meshes much larger than the drug providing rapid diffusive mediated release of drug 
molecules and meshes on the same or smaller size scale than drugs being mediated 
primarily through degradation or slow diffusive release.45 Because of this, as a handle for 
tuning drug release, hydrogel mesh size is often restricted for utilization with large 
molecules such as proteins or plasmids. 
 
Figure 1.7. Influence of mesh size on encapsulated drug release from hydrogels. 
Hydrogel mesh size influences drug release by exerting an effect on diffusive, 
degradation, or swelling mediated drug release. The degree to which hydrogel mesh 
influences drug retention/release is largely dependant on the relative size scales of the 
mesh size and drug payload. Adapted from Li et al.45  
 
 Finally, drug release may be influenced at the nano scale through control of 
payload interactions with the hydrogel. Covalent conjugation strategies may be utilized 
to directly immobilize therapeutics on the hydrogel, with linkages being designed to be 
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stable or cleavable under a variety of conditions (Figure 1.8).46 Furthermore, non-
covalent interactions, such as electrostatic or hydrophobic interactions may also be used 
to introduce an affinity of therapeutics to the hydrogel, and subsequent slower release 
properties.45 While these strategies may be used for large molecule therapeutics, they 
are almost exclusively used to manipulate the release of small molecules from hydrogel 
materials.  
 
Figure 1.8. Chemical interactions between payload and hydrogel may influence 
drug release properties. Designing chemical interactions into the hydrogel provides 
another mechanism for controlling drug release properties. This may be achieved 
through covalent conjugation of drugs to the hydrogel, or by designing electrostatic or 
hydrophobic interaction into the hydrogel material to provide affinity to the hydrogel for 
the payload molecule.  
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 A variety of protein-based payloads have been delivered to the heart, targeting a 
number of biological steps after MI.47 In one approach, hydrogels were used to deliver 
anti-apoptotic molecules in order to attenuate cell death following MI.48 In one study, 
Ruvinov et al. developed alginate microspheres encapsulating insulin-like growth factor 
1 (IGF-1) and hepatocyte growth factor (HGF).48 IGF-1 is a cytoprotective factor while 
HGF has angiogenic and anti-fibrotic properties. These microspheres were administered 
to the infarct to provide a sustained release of both drugs, with the hypothesis that there 
would be a cumulative effect from both factors. Injection of these microspheres after MI 
showed improvements in key markers such as reduction in fibrotic area, improvement in 
apoptotic cells, increased vessel densities and proliferation of cardiomyocytes at 4 
weeks after injection, as compared to factors injected in saline and blank microspheres.  
IGF-1 has also been used in other classes of hydrogels, such as a self-
assembling peptide based hydrogel designed by Davis et al.49 This material utilized 
streptavidin-biotin binding to provide long-term release of IGF-1 (84 days) and showed 
significant functional benefits when the hydrogels were utilized to co-deliver IGF-1 and 
neonatal cardiomyocytes. IGF has also been delivered using a PEG-based self-
assembling block copolymer system that can be administered using catheter-based 
approaches. This material has shown efficacy in improving functional outcomes such as 
ejection fraction, as well as improvement in tissue-level outcomes such as the formation 
of new cardiomyocytes, and increased vascularization.50 
In addition to targeting cytoprotection, hydrogels have been widely used for the 
delivery of angiogenic proteins, as a means to promote neovascular formation in the 
ischemic myocardium. One factor, fibroblast growth factor (FGF) has been used as a 
payload in a variety of hydrogel systems51-56. While FGF is a potent stimulator of 
angiogenesis, it suffers from a very short half-life in-vivo. As a means to address this 
limitation, Sakakibara et al utilized gelatin hydrogel microspheres as a delivery vehicle 
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for FGF, and showed through radiolabeling studies that effective doses of FGF could be 
sustained in the myocardium.52 Furthermore, this corresponded to improvements in LV 
remodeling and neovasculature formation at 4 weeks after MI. This growth factor has 
also been delivered from a variety of other hydrogels, including thermoresponsive 
chitosan hydrogels.51  
Vascular endothelial growth factor (VEGF), a stimulator of proliferation and 
migration in endothelial cells, has frequently been delivered to stimulate the growth of 
new vessels. While this is a key component in angiogenesis, often vessels require the 
recruitment and proliferation of smooth muscle cells to provide appropriate maturation. 
This dual delivery approach has been conducted using simple alginate hydrogels, as 
well as coacervates to provide for further control of release timing for each of these 
molecules.57,58 These approaches have shown success in the generation of αSMA 
positive vessels over either growth factor individually, as well as benefits to cardiac 
function. In addition to delivering these factors as freely soluble components, other 
groups have immobilized angiogenic factors on hydrogel surfaces to provide a sustained 
effect after injection. For example, Wu et al. immobilized VEGF to PEG block 
copolymers using NHS chemistry.59 These VEGF modified block copolymers were 
thermoresponsive, to provide a gelation mechanism after injection into the myocardium. 
Results from this study showed improved cardiac function and tissue morphology (scar 
fraction, capillary density) in hydrogels modified with VEGF as opposed to unmodified 
hydrogels, suggesting that immobilized proteins are also an effective strategy for 
inducing biological responses in the myocardium. 
Other recent strategies focus on delivering therapeutics that manipulate cell 
recruitment and cell proliferation in the myocardium. In one strategy, stromal derived 
factor-1 alpha (SDF-1α) was utilized for its ability to recruit progenitor cells. SDF-1α has 
been delivered via covalent immobilization to self-assembling peptide hydrogels, as well 
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as encapsulation in hyaluronic acid hydrogels.60-62 These strategies have shown 
structural benefits, including an increase in progenitor cells possessing the receptor for 
SDF and a concomitant increase in capillary density, as well as benefits in cardiac 
function. Furthermore, other SDF analogs have been delivered in order to improve the 
stability of the chemokine signal, as SDF is susceptible to protease degradation.61 Other 
strategies focus on directly improving proliferation of non-proliferative cardiomyocytes. 
Mir-302, a micro RNA influencing transcription along the Hippo pathway, was delivered 
using an injectable hyaluronic acid hydrogel.63 Utilizing a confetti mouse model, the 
study showed the ability for this payload to stimulate clonal expansion of 
cardiomyocytes, which contributed to overall improvements in cardiac function.  
One final strategy that hydrogels have employed for drug delivery is the delivery 
of inhibitors for MMPs. Proteases are maladaptively upregulated in the infarct tissue, and 
inhibition of this activity has lead to improved outcomes through the use of systemically 
administered protease inhibitors.22,64-67 Local delivery with hydrogels, however, 
attenuates off-target effects of these inhibitors on normal matrix turnover, which is 
important to mitigating harmful side effects of these molecules during systemic 
administration. TIMPs are protein-based inhibitors that the body uses to regulate MMP 
activity. As a strategy for local MMP inhibition, TIMP-3 has been delivered locally from 
injectable hydrogels in pig studies.68 As a means to provide different mechanisms of 
control, TIMP-3 was delivered passively using covalently crosslinked hydrogels, or in 
response to protease degradation in protease cleavable hydrogels.68,69 These systems 
showed the benefit of TIMP-3 payload in hydrogels on local MMP activity as well as 
ventricular geometry and function. This strategy has also been employed utilizing 
peptide-based inhibitors delivered using a thermogelling system based on NIPAAM, 
which showed an ability to decrease MMP activity and improvements in ventricular 




MI is a widely prevalent condition that leads to an array of progressive changes 
in the heart, which ultimately may contribute to long-term heart failure. Current treatment 
methods fail to address the underlying biological changes that occur after an infarction at 
the acute time points, driving a need for improved therapies. As a result, injectable 
hydrogels have developed into a burgeoning field of cardiac intervention, providing 
mechanical support in the left ventricle after MI. These materials have subsequently 
been used to further address the underlying biology as drug delivery vehicles, delivering 
a variety of payloads locally that can attenuate cell death, promote cell recruitment and 
proliferation, generate new vasculature, or provide inhibition of MMPs.  
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2.1 SPECIFIC AIMS 
It is clear that biomaterials are emerging to have an important role in the 
treatment of various cardiac diseases and conditions.1-7 Specifically, hydrogels (water-
swollen polymer networks) are being developed to treat patients after myocardial 
infarction (MI), due to their tunable properties and potential for percutaneous delivery to 
the heart.6 Hydrogels are comprised of either natural or synthetic polymers and can be 
used to influence mechanical properties in the myocardium or as a delivery vehicle to 
improve the retention and viability of cells or the sustained delivery of therapeutics.6,8-10  
Self-assembled hydrogels, formed using reversible, non-covalent bonds as 
crosslinks, are one class of hydrogels that possess a number of unique properties that 
make them highly amenable for clinical translation in myocardial applications.11 
Specifically, these materials are shear-thinning and self-healing, allowing them to be 
easily injected.12,13 This is often advantageous when compared to traditional covalent 
systems that suffer from issues associated with reaction times that can lead to difficulty 
in handling by clinicians (e.g., clogging of delivery devices), as well as the potential for 
extravasation when injected into tissue.11 In comparison, shear-thinning allows for 
injection through a variety of syringes and catheters, while self-healing allows hydrogels 
to re-form when they reach the desired tissue site. 
Our lab has recently developed a two-component hydrogel system based on 
hyaluronic acid (HA) that has been engineered for injection into the myocardium.4,13 HA 
is a highly useful polymer for hydrogel design, as it is a naturally occurring component of 
the extracellular matrix and is easily amenable to orthogonal chemical modification.14 
This developed hydrogel is crosslinked through the directed self-assembly or guest-host 
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(GH) chemistry between the hydrophobic cavity of β-cyclodextrin (CD) and the 
hydrophobic small molecule adamantane (Ad). Simply, HA is modified with either CD or 
Ad (CD-HA, Ad-HA) and gelation occurs when the two solutions of CD-HA and Ad-HA 
are mixed, to form a hydrogel with shear-thinning and self-healing behavior.13  
Although this general hydrogel system has been explored previously to alter 
myocardial mechanics and for the delivery of several molecules (e.g., microRNA, 
extracellular vesicles), there is still much work to expand the hydrogel to the widespread 
therapeutics that are of interest to treat patients after MI. 4,5,15,16 To address this, the 
overarching objective of this thesis is to advance GH assembled materials for the 
delivery of small molecule therapeutics, as well as to design new GH assembled 
materials with complex multifunctional properties. The following aims serve to guide this 
objective, investigating material structure and properties that govern their therapeutic 
efficacy in influencing the remodeling myocardium after an infarction.  
 
Aim 1: Design an easily injectable guest-host hydrogel formulation for sustained 
small molecule delivery 
Hypothesis: The host molecule (CD) within GH hydrogels will bind to encapsulated small 
molecules to sustain and control their release behavior from hydrogels.  
 
Hydrogels are often unable to serve as a delivery platform for small molecules, 
as their large mesh sizes lead to the rapid diffusion of small molecules.17 Specifically, 
hydrogels are inherently highly swollen in nature, providing minimal diffusive barriers for 
encapsulated small molecule drugs, as their molecular mesh size is often much greater 
than the entrapped molecule. This rapid diffusion limits the sustained release potential 
for small molecule drugs from hydrogels. CD, with its cyclic structure and hydrophobic 
core, is known to bind to many small hydrophobic molecules and has been used 
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frequently as an excipient in the pharmaceutical industry to improve solubility and 
absorption of hydrophobic small molecules.18,19 Given this broad affinity for small 
molecules, we design hydrogels through GH assembly, leveraging CD for both hydrogel 
formation and to retain small molecules within hydrogels. Molecule binding, diffusivity, 
and release when encapsulated are explored as a function of hydrogel composition 
(e.g., ratio of Ad:CD, polymer concentration).  These studies expand our knowledge of 
drug binding to sustain release from hydrogels and point to specific formulations that 
may be investigated for treating MI.  
 
Aim 2: Release a small molecule protease inhibitor from an injectable GH hydrogel 
for treatment of MI 
Hypothesis: A small molecule protease inhibitor SD-7300 can be released in a sustained 
manner from GH hydrogels to improve functional and biological outcomes after MI when 
compared to hydrogels alone or saline treatment.  
 
Spatial inhibition of MMPs throughout the body, targeting of MMP subtypes, and 
timing of MMP inhibition have been shown to play key roles in therapeutic benefit of 
targeting MMP activity for therapeutics.20-25 This paradigm has translated to the 
development of numerous small molecule inhibitors; however, off-target effects related 
to the systemic delivery of broad-spectrum MMP knockdown has limited their translation. 
For example, SD-7300, an MMP-1 sparing small molecule inhibitor (Pfizer), has shown 
pre-clinical potential as an MI therapeutic, but only with off-target effects. Thus, the local 
delivery of SD-7300 may overcome these limitations.  To address this, we develop a 
specific injectable GH hydrogel formulation, where interactions with CD lead to sustained 
release.  Further, a large animal model of ischemia-reperfusion in swine is used to 
demonstrate the ability of the injectable hydrogel delivering SD-7300 to alter remodeling 
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outcomes and improve functional outcomes.  These studies provide an innovative 
approach for targeted, localized MMP inhibition in the infarcted myocardium with broad 
impacts on evolving strategies for pharmaceutical MMP inhibitor therapies.  
 
Aim 3: Develop an injectable granular hydrogel system for treatment of MI  
Hypothesis: Shear-thinning hydrogels can be assembled through the GH interactions of 
polymers and microgel components with properties of degradation, molecule release, 
and cell invasion based on microgel design.  
 
Towards designing material systems for application in the myocardium, it is 
important to consider multifunctional behavior including drug release, cell invasion, and 
microstructure. These properties are difficult to integrate into a single injectable material, 
limiting the scope of biomaterial-based approaches in MI interventions. Emerging 
classes of materials with potential to design modular, multi-therapeutic release systems 
include granular hydrogels, where microgels are assembled into a bulk hydrogel. 26-28 As 
GH chemistry provides a directed and highly controllable mechanism of self-assembly, 
we engineer unique materials based on the assembly of covalently-crosslinked 
microgels modified with Ad with CD-HA polymers. We investigate the rheological 
properties of these materials, as well as the degradation and release behavior of 
granular hydrogels assembled through microgels crosslinked with either stable or 
protease-degradable crosslinks.  Further, these materials are investigated after injection 
into a rat model of MI, where features such as microgel erosion and the ability to alter 
remodeling outcomes are investigated.  Thus, this aim designs innovative, multi-scale 
materials using the self-assembly of microgel components to provide multi-functional 
benefit in the infarcted myocardium. 
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2.2 CHAPTER OUTLINE 
Chapter 1 provides an in depth overview of MI and a summary of the biological 
mechanisms behind left ventricular remodeling.  Further, the various hydrogel 
approaches and specific systems that have been pursued for treating MI, including 
through mechanical intervention, cell delivery, and drug delivery are summarized. 
Chapter 3 shows a more focused review of GH assembled biomaterials, including the 
various GH pairs that have been explored in the development of biomaterials and their 
role in drug delivery and other therapeutic applications.  
Chapter 4 describes the scientific research proposed in Aim 1, outlining the 
tunable parameters in GH hydrogels for the sustained release of a variety of therapeutic 
small molecules payloads. Chapter 5 describes the scientific research proposed in Aim 
2, outlining the development of a GH formulation suitable for the delivery of SD-7300 
and its application in a porcine model for MI. Chapter 6 describes the scientific research 
proposed in Aim 3, outlining the development of a multifunctional granular hydrogel and 
its application in a rat model for MI.  
Finally, Chapter 7 provides a summary of the work presented, illuminating the overall 
impact of GH hydrogel systems for the delivery of therapeutics after MI. Limitations of 
these material systems are discussed, and potential future directions are proposed that 
may further expand the application of these hydrogels.  
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While chemists have traditionally focused on methods of assembling atoms and 
molecules through the formation and rearrangement of covalent bonds, it has been 
elegantly noted that this strategy pales in comparison to the array of possible 
interactions utilized in nature to develop large, complex molecular structures through 
non-covalent bonds.1 These interactions are encompassed within the field of 
supramolecular chemistry, which includes electrostatics, hydrogen bonding, van der 
Waals forces, п-п interactions, and hydrophobic or hydrophilic attraction for molecular 
assembly.2 While such interactions have long been known, the field has continued to 
rapidly expand since the 1987 Nobel Prize was awarded to Pedersen,3 Cram,4 and 
Lehn5  for their pioneering work in formalizing synthetic methods in this area.   
Lehn described the concept of supramolecular assembly as “chemistry beyond 
the molecule.” 5 This is because the non-covalent nature of supramolecular bonds 
renders them inherently weaker than covalent bonds and they may therefore exhibit 
thermodynamic or forcefully induced rearrangement. As a result, supramolecular bonds 
display a capacity for directed assembly at length scales far exceeding that of single 
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atoms or molecules, such as with the formation of higher order structures in biological 
proteins and tissues. The capacity for spontaneous and reversible binding between 
molecular species is likewise a driving force in the development of structured,6-8 
dynamic,9 and self-healing10 materials, as well as in pharmaceutical applications11-13 and 
directed cell-material interactions which will be discussed herein.   
One particular subset of supramolecular chemistry, namely guest-host 
interactions, is of particular interest toward the biomedical community. These bonds are 
based on the transient association of a molecule containing a cavity (i.e. a cavitand) with 
suitable molecular guests. The family of cavitands includes both naturally-derived (e.g. 
cyclodextrin) and synthetic (e.g. cucurbit[n]urils, calix[n]arenes, and pillar[n]arenes) 
macrocycles.12,14-16 The criteria for a guest-host pair involves complementary size of the 
host cavity and guest molecule, as well as their specific interactions (predominantly 
through hydrophobic attraction).17,18 These broad criteria lend themselves to the pairing 
of macrocycles with numerous potential guests, which may be inert or stimuli-responsive 
molecules, pharmaceuticals, biomolecules (i.e. peptides, proteins), polymers, or other 
chemical species. Owing to the array of guest and host molecules and their synthetic 
flexibility, incorporation of these groups into polymeric materials may be easily achieved 
for a diverse range of biomedical applications. Despite recent developments in polymeric 
guest-host materials, there remains a tremendous capacity for growth in the biomaterial 
utilization of these unique chemistries. Toward elucidating these future directions, this 
review will highlight recent advances in both our understanding and application of 
materials and interactions mediated by guest-host macrocycle assembly.  
 
3.2. MECHANISMS OF SELF-ASSEMBLY 
3.2.1. DIRECT MOLECULAR RECOGNITION 
 37	  
Supramolecular assembly may be ambiguous, with non-specific interactions 
between numerous groups. Examples of such interactions in material assembly include 
the formation of hydrophobic crystalline domains or charge-based assembly of 
polyelectrolyte or polyampholyte polymers. These interactions may be preferable in 
some cases, such as to facilitate incorporation of hydrophobic19,20 or charged drugs21,22. 
However, such assembly processes involve development of long-range order over 
relatively long timescales, which may hamper rapid formation and recovery. Moreover, 
the prevalence of competitive binding groups (i.e. any non-charged molecule, salts) may 
disrupt bond formation and material assembly. Thus, it is important to define 
supramolecular interactions that have more specific associations to fabricate robust 
materials for biomedical interactions. 
Toward this, direct associating systems are based on specific molecular 
recognition of a guest by its corresponding host molecule upon mixing (Figure 3.1). 
Such direct interactions do not require long-range order and therefore occur rapidly, with 
timescales governed by the association constant (ka), enabling rapid initial material 
formation and self-healing upon rupture. Numerous molecular structures have been 
identified and designed to form guest-host pairs. These include the relatively weak 
association of crown ethers, cryptands, and related molecules;23,24 though, such 
associations are generally more suited for ionic sequestration and not molecular 
recognition. Alternatively, an array of transient peptide and/or protein interactions have 
been devised,25-29 which often display greater affinity and specificity, but at the cost of 
increasing complexity and laborious synthesis. Finally, the guest-host macrocycles 
combine rapid, high affinity molecular recognition with ease and scalability of synthesis.   
Of the guest macrocycles, cyclodextrin (CD) is the most prevalent due to its 
relatively high water solubility, low toxicity, and extensive history of use. The first 
reference to CD was that of Villiers, in 1891, who isolated a crystalline substance 
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following bacterial digestion of cellulose.30 While research continued on the formation 
and characterization of these crystalline dextrans, nearly half a century passed before 
their cyclic structure was proposed (D-glucose units arranged in a toroidal fashion 
through α-1,4 glycosidic bonds) and isolation of homogenous fractions of α, β, and γ 
cyclodextrin (which contain 6, 7, or 8 repeat units, respectively) was accomplished.14 
Importantly, improvements toward these synthesis and purification processes have 
proceeded to industrial scale, as have many strategies for their synthetic modification, 
resulting in a relatively cheap and abundant material source.14,31 Enabled by the 
scalability of synthesis, CD molecules are used in a variety of industrial, commercial, and 
pharmaceutical applications and have been categorized by the Food and Drug 
Administration as “generally recognized as safe” (GRAS).32-34 Moreover, the cavity sizes 
of CDs allow them to include a range of guest hydrophobic molecules in its interior. Of 
these potential guest molecules, adamantane (Ad) is widely regarded as having one of 
the greatest affinities (Keq ≈ 105 M-1) due to its complementary size for βCD and high 
hydrophobicity.35 Alternatively, responsive guest-host interactions have emerged as a 
means of regulating these intramolecular interactions. These include azobenzene and 
ferrocene, which are known to interact with numerous species of CD and are responsive 
to light36 and redox conditions,37,38 respectively.  This behavior renders them particularly 
useful toward the development of responsive delivery vehicles,39  actuating materials,40,41 
and dynamically assembling systems.42-44  
More recently, alternate cavitands have emerged and demonstrated relevance 
toward biomedical applications. This second generation of cavitands includes 
cucurbit[n]urils (CBs), pillar[n]arenes, and calix[n]arenes. While CBs were first prepared 
in 1905,45 investigation of their structure was not performed until 1981,46 and numerous 
CBs (typically 5-10 repeat units) have since been explored. Recent examination has 
revealed mild in vitro toxicity of these groups, though only at doses far exceeding those 
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typical in vivo, supporting their continued pharmaceutical use.47 Binding affinities for CBs 
are often greater than that of other cavitands and can reach values as high as Keq ≈ 1015 
M-1.48 This may be attributed, in part, to the binding of guest molecules through a 
combination of hydrophobic and cation-dipole interactions.48-50 Moreover, the unique 
geometry of CB[8]s allows for multivalent binding of guest molecules (such as 
naphthalene and methyl viologen), which enables reinforcement of binding affinity by 
cooperation between п-п stacking or charge-transfer interactions for guest-host complex 
formation.51 Recently, the use of the cup-shaped calix[n]arenes and pillar-shaped 
pillar[n]arenes toward biomedical applications has begun.12 Their translation to this field 
has been previously hampered both by lower guest-host affinity and water solubility 
when compared to their CD and CB counterparts; though, recent work has sought to 
improve the affinity and water solubility of these macrocycles such as through repeated 
and efficient modification with solubilizing functional groups,52 resulting in macrocycles 
with improved utility in aqueous environments.  
 
 
Figure 3.1. Molecular guest-host assembly. (A) Generalized schematic of host (red) 
interaction with its corresponding guest (blue) to form a guest-host complex (purple), 
with bonding equilibrium governed by the association (ka) and dissociation (kd) 
constants. (B) Schematic representation of cavitand host species, represented by 




3.2.2. POLYMERIC ASSEMBLY 
Guest-host molecular recognition is particularly useful for the formation of 
supramolecular structures (i.e. guest-host hydrogels). Toward hydrogel formation, 
pioneering work by Harada demonstrated that poly(ethylene oxide) (PEO) could be 
threaded within multiple αCD moieties, yielding a rotaxane structure.53 Pursuit of such 
systems further illustrated the formation of pseudopolyrotaxanes and a sol-gel transition 
upon simple mixing of PEO and αCD through crystallization of CD domains (Figure 
3.2A).54 These and similarly formed pseudopolyrotaxanes, such as through pendant 
polymer modification with PEO or similar polymers (Figure 3.2B),  have since become a 
basis for supramolecular assembled hydrogels which have been separately reviewed.55 
Such systems may be limited in therapeutic use, due to long recovery times after 
injection,56 which may hinder injection site retention, and the inaccessibility of CD in the 
network to interact with surrounding molecules.  
Alternatively, modification of polymers with guest and host groups (either as end-
groups or pendant modification) has become the primary method for fabrication of 
supramolecular networks from guest-host interactions. For example, the end-
modification of mono- and bifunctional polymers has been examined (Figure 3.2C),	  
where potential applications may include the self-sorting of linear supramolecular 
polymers or assembly of block copolymers with utility toward such materials as 
responsive micelle assembly.57-59 In extension of this methodology, multiarm PEO has 
been modified with either βCD or cholesterol (the guest molecule) and van de Manakker 
and colleagues demonstrated formation of supramolecular hydrogels by mixing these 
precursors with controllable rheological erosion, and cargo release profiles. 60,61 
Similarly, Charlot et al. extensively explored the rheological behavior of binary 
associating systems by conjugating βCD and Ad to chitosan, hyaluronic acid (HA), and 
other polymers as pendant groups (Figure 3.2D). While low modification resulted in 
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weak supramolecular networks (typical G’ < 100Pa), their results demonstrated the 
importance of polymer concentration, charge, and competitive binding on network 
assembly.62 Moreover, theoretical and experimental approaches have been combined to 
illustrate the importance of multivalent and inter-polymer interaction to generate high 
avidity and network stability.63,64 Toward harnessing this understanding, our group has 
demonstrated that higher degrees of modification of HA with these same guest-host 
groups enables formation of more robust supramolecular hydrogels (G’ = 10 kPa 
possible) through generation of larger net avidity between polymers which may be 
enhanced by multifold polymer junctions.65  
CB macrocycles have also been explored to produce robust supramolecular 
hydrogels. This work has been pioneered by the Scherman group, where polymers were 
modified with pendant methyl viologen or napthoxy derivatives that form ternary 
complexes with soluble CB[8] with high affinity (Ka ≥ 1011 M-2, Figure 3.2E). Such 
materials resulted in good network mechanical properties (typical G’ > 500Pa) even at 
low polymer modification (5-10% of repeats).66,67 For further information regarding 
polymer architecture and molecular organization in guest-host hydrogels and their 
influence on bulk hydrogel properties, the reader is referred to extensive reviews that 
cover these topics.2,68 
Beyond the ability to assemble into networks, supramolecular guest-host 
interactions may be used to introduce structure at the nano- and micro-scales. Indeed, 
the organization of many natural structures is driven by supramolecular interactions, 
such as native extracellular matrix (e.g., fibrillar structure of collagen) and the DNA 
superstructure. Such aspects may be recapitulated by synthetic analogues.69,70 
Observations of such behavior have been noted in numerous self-assembling systems 
including peptide amphiphiles71, DNA-based hydrogels72, dendritic materials8, and PEG-
based supramolecular systems73. In recent years, there have been numerous reports 
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indicating that similar hierarchical structures are possible in guest-host hydrogels, 
though most include only observation of dried samples by electron microscopy. Recent 
reports have shown the formation of nanoparticles with well controlled size through 
synthesis of diblock copolymers containing βCD.74 Moving this structure into two-
dimensional assembly, semi-rigid four-arm macromolecules have been modified by 
methyl viologen and 2,6-dihydroxynaphthalene which assemble into two-dimensional 
films upon mixing with CB[8] in water. Both TEM and AFM confirmed a nanofibrillar 
structure, and SAXS estimated the spacing of these features to be well approximated by 
the theoretical pore size.75 In an interesting example of three-dimensional structure, 
aggregation of N-isopropylacrylamide (NIPAAM) thermogels has been controlled by 
introducing CB[7] as polypseudorotaxane side chains. Such inclusion results in semi-
rigid polymer segments that induce transition from a globular to porous morphology that 
could be observed by optical microscopy in a hydrated state.76 Control of physical 
structure on these length scales holds great promise for the cell biology and biomaterials 
fields, as dynamic self-assembly of these structures may best recapitulate the natural 
processes that drive cell behavior. Though, systematic studies including the effects of 






Figure 3.2. Schematic representation of guest-host polymeric assemblies. (A, B) 
CD-PEO pseudopolyrotaxanes; (C) supramolecular polymers from heterobifunctional (i), 
homobifunctional (ii), and monobifunctional (iii) gelators;  (D) separate, pendant 
modification by βCD and adamantane; and (E) separate, pendant modification of 
polymers by methyl viologen or napthoxy derivatives with crosslinking by ternary 
complexes with soluble CB[8]. 
 
 
3.3. DIVERSE BIOMEDICAL APPLICATIONS 
3.3.1. INJECTABLE HYDROGELS 
  Injectable materials have become important in the biomaterials community as 
they can be introduced in a minimally invasive manner through direct injection into a 
tissue or via catheters. Many methodologies exist for formation of injectable materials, 
including in situ gelling via initiated or autonomous polymerization, addition crosslinking, 
or thermogelation; however, there are numerous limitations to such systems based on 
gelation kinetics (i.e. too fast leads to clogging of delivery device, too slow leads to 
material dispersion upon injection). Alternatively, guest-host hydrogels may be formed 
prior to injection (Figure 3.3A, i) and extruded via shear-induced flow. Such shear-
thinning properties are of interest for numerous supramolecular hydrogels,77 due to their 
dynamic bonds that can be broken and then reformed. Many practical requirements 
should be considered when designing guest-host hydrogels as deliverable materials, 
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such as the injection process (i.e., ease of injection and capacity for retention), as well 
as the subsequent physical properties after injection (i.e., suitable moduli and 
degradation times).  
  For shear-thinning materials, the injection process is governed by the material 
response to shear stress; ideally, the material is pre-formed and then exhibits a 
decrease in viscosity (i.e., shear-thinning) during injection that permits flow. Indeed, this 
is the case for the majority of supramolecular materials, as the physical bonds that 
permit assembly are temporarily broken (Figure 3.3A, ii). The kinetics of bond 
formation, though, are of key interest to the shear response of hydrogels. Craig and 
coworkers extensively studied the relationship of bond kinetics and polymer relaxation 
timescales, demonstrating that disadvantageous shear-thickening behavior arises if 
polymer relaxation occurs more rapidly than reconnection of broken crosslinks.78,79 As 
such, the decreased polymer relaxation may be accomplished through formation of 
multifold junctions in highly modified guest-host hydrogels to enforce shear-thinning 
behavior and ease of injection.80 The physical chemistry underlying the flow process, as 
well as other fundamental behaviors of supramolecular networks have been recently 
reviewed.9 Beyond regulating flow properties, the binding kinetics are also essential 
toward material formation following injection (Figure 3.3A, iii), as rapid bond reformation 
is essential for material retention. In recent work, we demonstrated that rapidly self-
healing guest-host hydrogels are well retained (>98% of initial hydrogel volume) upon 
injection into myocardial tissue, whereas slowly crosslinking covalent controls were not 
retained as gelation was too slow.81 This high material retention is essential, including 
toward successful implementation of injectable materials as tissue supplements, drug 
reservoirs, or cell delivery vehicles as discussed in subsequent sections. 
  Also critical to the success of injected biomaterials are the final properties in vivo, 
following injection. In many cases, material degradation may be desired to eliminate the 
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need for implant removal or permanent implantation. Guest-host assembled materials 
are of great utility toward this, as they undergo natural disassembly due to their dynamic 
bonds (Figure 3.3A, iv). Thus, their rate of degradation can be controlled through 
features such as material concentration, guest-host affinity, and number of guest-host 
bonds.61,80 Additionally, the degradation rate of such materials may be altered by 
inclusion of conventional degradation mechanisms, including hydrolysis or enzymatic 
degradation. Toward such control of degradation, Tian et al utilized a hydrolytically 
degradable poly(organophosphazine) backbone grafted with PEO of differing molecular 
weights. In the presence of soluble αCD, hydrogels were formed which exhibited 
controlled release of bovine serum albumin (BSA) over a period of 2-12 days, with 
concurrent and prolonged hydrogel degradation.82 More recently, bioactive degradation 
mechanisms have been demonstrated; in one embodiment, micelles and hydrogels were 
formed through inclusion of glutathione in the micelle core to enable bioreduction of the 
polymeric structures which controlled release of doxorubicin.83 Additionally, pendant Ad 
modification of HA has included a peptide linker susceptible to cleavage by matrix 
metalloproteinases (MMPs) that are naturally produced in remodeling of the extracellular 
matrix. When combined with pendant modified βCD-HA, hydrogels were formed which 
exhibited enhanced degradation in the presence of mammalian MMP-2.84 These means 
of degradation are of interest to the biomedical community to ensure clearance of the 
eroded materials (e.g. failed renal clearance of high molecular weight PEO may limit 
applicability of αCD-PEO hydrogels without inclusion of such hydrolysis mechanisms) 
and because bioresponsive degradation perpetuates such applications as on-demand 
drug release and tissue-material integration. 
As an alternative to enhanced degradation, prolonged material presence may be 
desirable.  Many supramolecularly assembled materials degrade in the course of days, 
which may be too rapid for numerous applications in cell delivery or tissue repair. One 
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approach to achieve improved degradation lifetimes is the use of higher affinity 
interactions, such as CB[8] with an electron transfer pair, which has enabled sustained 
release of biomolecules (BSA and lysozyme) for up to 160 days in vitro.85	   Interaction of 
CB[6] and polyamine modified HA has also been used, but implantation was achieved 
not by shear-thinning injection but instead by sequential subcutaneous injection of the 
two components, with supramolecular assembly in vivo. Inclusion of fluorescently 
labeled CB[6] in the hydrogel demonstrated presence as long as 11 days, whereas the 
free fluorophore was released within 24 hours as examined by in vivo fluorescence 
imaging.86 These approaches demonstrate the capacity for high affinity guest-host pairs 
to provide prolonged delivery of biomolecules by diffusion or through modular 
modification with the host molecule, though such high affinity guest-host interactions 
may limit shear-thinning properties, hindering their use as injectable materials.87 
Alternatively, the use of secondary stabilization chemistries, subsequent to 
supramolecular bonding, has been achieved to enhance mechanical stability without 
affecting injectability. Such processes have been accomplished in protein-based 
supramolecular assembly using photopolymerization or thermogelation as secondary 
gelation mechanisms.28,88 To allow for in vivo crosslinking and long-term mechanical 
stability, we have recently introduced secondary crosslinking in vivo through 
autonomous Michael addition, enabling covalent crosslinking on clinically relevant 
timescales. Application in a rodent model of myocardial infarct (MI) demonstrated a 
capacity for mechanical stabilization of the injured tissue, tending to improve geometrical 
and functional outcomes relative to untreated MI or guest-host material controls without 
secondary crosslinking.81 Though, care should be taken in these approaches, as rapid 




Figure 3.3. Guest-host hydrogel injection. (A) Hydrogels are pre-formed within the 
syringe through guest-host bonds (i) which are broken by shear stress (τ) within the 
needle (ii). Following extrusion, bonds rapidly re-form (iii) to enable retention within the 
tissue. Subsequent disassembly of the hydrogel in vivo occurs through spontaneous 
dissociation of the dynamic bonds and resultant surface erosion of the polymer (iv). (B) 
Representative oscillatory time sweep demonstrating initial hydrogel mechanics (i), 
yielding to enable flow under high strain (ii), and rapid recovery (iii) such as that 
proposed for injection. Adapted from Charlot et al. 63 
 
 
3.3.2. THERAPEUTIC DELIVERY 
In addition to formation of injectable materials by guest-host mediated self-
assembly, these unique interactions have significant applications in drug delivery 
strategies. The most widely used materials in this field have been the CD macrocycles, 
as they have been used in many pharmacological drug formulations including 
Sporanox©, Yaz©, and Abilify© among others.89 CDs form inclusion complexes with 
various drugs, which improves the drug bioavailabilty by increasing drug solubility and 
protecting them from degradation, which has been reviewed extensively 
elsewhere.13,89,90 Guest-host interactions have also been used recently to develop 
materials as drug delivery systems, providing novel biofunctionality through non-covalent 
conjugation of bioactive pendant groups, as well as the development of bulk materials to 
provide the controlled release of growth factors, genetic material, and small molecule 
therapeutics. 
While improving the physiochemical properties of drugs has prevailed in the 
translational application of guest-host complexes, more advanced nanoparticle systems 
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are also being developed. These systems leverage the formation of guest-host 
complexes as a conjugation strategy to provide stealth or targeting, or to allow 
nanoparticles to carry hydrophobic payloads (Figure 3.4A). Work from the Davis group 
provides an excellent example of exploiting guest-host complexes in delivery systems 
that have translated to clinical trials.91 They developed CD functionalized polymer 
backbones that form polyplexes with siRNA payloads, with surfaces that may be 
decorated with Ad coupled macromolecules such as PEG or transferrin.92-94 This type of 
conjugation allows for rapid and modular modification of particle systems with a variety 
of ligands. Similar non-covalent conjugation strategies have been employed using other 
guest-host pairs such as CB[6] with polyamines to provide targeted delivery of 
nanocapsules.95,96 In addition to strategies for noncovalent surface modification, 
macrocycles have been incorporated into nanoparticles to act as molecular “docking” 
sites that can facilitate drug loading (Figure 3.4B). This carrier functionality has been 
exploited using amphiphilic CD nanocapsules to entrap tamoxifen, ionic βCD 
nanoparticles as doxorubicin carriers, and CB[6] particles to carry paclitaxel.96-98 
Furthermore, macrocycle interactions have provided an avenue for direct, noncovalent 
conjugation of biofunctional groups to drug molecules (Figure 3.4C). As examples, βCD 
functionalized with lactoferrin and saccharide ligands has been used to complex and 
target drugs to lactoferrin and mannose receptors, respectively.99,100  
In addition to nanoparticle strategies, guest-host systems have been leveraged in 
bulk hydrogels to provide controlled release of therapeutic payloads. Many groups have 
employed guest-host assembly to drive the formation of hydrogels that can provide 
sustained release of biomolecule payloads such as proteins and growth factors (Figure 
3.4D). These systems provide diffusive release kinetics that may be tuned through 
network properties such as porosity, mesh size, and degradation, which may in part be 
mediated by dynamic supramolecular interactions. For example, Liu et al used 
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polyrotaxane assembly between αCD and tri-block copolymers to form gels that display 
tunable sustained release of dextran molecules as a model for release.101 Furthermore, 
the Scherman group developed systems based on CB[8] assembly that provide tunable 
release of bioactive proteins over sustained periods in vitro, as previously discussed.85 
Finally, work from the Hennink group as well as our own have shown tunable protein 
release from βCD-based hydrogels, where crosslink density was used to control release 
for up to 60 days.65,102 These applications have recently been extended in vivo, where 
the guest-host hydrogel was used as an injectable material for diffusive local delivery of 
multiple biomolecules (interleukin-10 and anti-transforming growth factor β) to treat 
chronic kidney injury.103 Similarly, hydrogels composed of αCD pseudopolyrotaxanes 
with PEO terminated block copolymers have been used as an injectable reservoir for 
delivery of erythropoietin (EPO) in a rodent model of MI. The therapy resulted in a 
tendency toward increased vascular density as well as a significant decline in apoptosis 
and increase in myocardial function (fractional shortening) as compared to saline, 
hydrogel alone, and soluble EPO injection. These examples demonstrate the 
multifaceted use of such material systems as an easily prepared injectable material to 
generate diffusively controlled drug delivery reservoirs in vivo.  
A last mechanism by which guest-host interactions can control release of 
molecules is through inclusion effects of therapeutics with macrocycles anchored to a 
polymer backbone (Figure 3.4E). Several groups have investigated covalently 
crosslinked hydrogels containing CD pendant groups to provide sustained release of 
small molecules.104-109 In one example, the von Recum group developed polyurethane 
gels containing CD as device coatings for the controlled release of numerous 
antibiotics.110 Work from our own group has also explored CD retentive effects for 
controlled release of small molecules including doxorubicin, doxycycline, and peptides 
containing tryptophan residues, from guest-host assembled networks, leveraging these 
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interactions to provide materials that are simultaneously injectable and exhibit sustained 
release properties.109 These systems provide tunable small molecule release through the 
engineering of host content, as well as the guest affinity for the host included in the 
network.  
 
Figure 3.4. Guest-host interactions in drug delivery systems. Guest-host chemistry 
may be used for direct, non-covalent modification of drug molecules with targeting 
ligands (A), to provide non-covalent modification of nanoparticle drug carriers with 
targeting or stealth ligands (B), and to impart molecular carrier functionality to 
nanoparticles (C). Furthermore, in hydrogel systems, guest-host chemistry may be used 
to tune crosslinks in hydrogels for the diffusive release of biomacromolecular 
therapeutics (D) or to promote retention of small molecule therapeutics within the 
hydrogel (E).  
 
3.3.3. CELL-MATERIAL INTERACTIONS  
While the above applications have targeted material implantation and therapeutic 
delivery through guest-host mediated assembly, still others have sought to develop 
methods for the direct modification of cell-material interactions using guest-host 
chemistry. These approaches to modulate cell-material interactions have primarily taken 
two forms: modification of material surfaces and the pursuit of material-assisted cell 
delivery.  
Surface modification strategies are useful to introduce various biophysical and 
biochemical signals to cells, and guest-host interactions provide an opportunity to 
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introduce dynamic signals that can alter cell behavior. Stupp and colleagues utilized the 
guest-host complexation of guest-bound adhesive peptide sequences to alginate-βCD 
surfaces to dynamically control biomolecule display.111 Specifically, they utilized the 
fibronectin derived cell-adhesion sequence RGD bound to the guest molecule Ad or 
naphthalene, suspended in culture medium, to impart cell adhesion and spreading on 
the material surface. Importantly, spreading was observed to be dependent on the 
affinity of the guest for βCD and was reversible when napthyl-RGD was removed by 
competitive binding with the higher affinity non-cell adhesive sequence Ad-RGES. In 
concurrent work, the Cooper-White group used supramolecular interactions to display 
RGD in nanopatterned topographies produced by the segregation of Ad terminated 
polystyrene-co-PEO block copolymers (PS-PEO-Ad).112 Such topographies are known to 
influence cell behaviors, including adhesion, spreading, and differentiation.113-115 The 
ratio of PS-PEO/PS-PEO-Ad used to control the concentration of βCD-RGD bound 
within the nanodomains influenced cell adhesion and area. Interestingly, the facile 
conjugation process enabled the concurrent addition of RGD and the laminin derived 
sequence IKVAV in set molar ratios, demonstrating similar adhesion across all ratios 
with spreading and stress fiber organization dependent on RGD concentration alone.  
These methods of dynamic surface modification have demonstrated promise 
toward influencing cell adhesion and spreading; however, little work has been performed 
to directly demonstrate influence over cell differentiation. There is a growing interest in 
the field to understand the effects of substrate properties on differentiation, as indicated 
by the recent use of covalently or ionically crosslinked hydrogels with tunable viscous 
behaviors (i.e., creep and viscoelasticity) to study differentiation.116-118 Toward 
understanding differentiation in response to mechanically dynamic substrates, αCD-PEO 
polyrotaxane coated surfaces have recently been explored. Here, the mobility of αCD 
was modulated by methacrylation—thus varying its affinity for PEO. Subsequent coating 
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of this polyrotaxane surface by fibronectin produced a cell-adhesive surface which 
demonstrated enhanced osteogenic differentiation in response to molecular mobility. 
Though, results are complicated by a lack of standardization in fibronectin density 
between groups.119  
Cell delivery for therapeutic applications is often problematic, as cells have 
limited retention at injection sites; however, hydrogels can be used to enhance cell 
retention, particularly with rapidly re-assembling hydrogels.88,120 Toward such a delivery 
approach, Kimoon Kim and colleagues have developed an in situ forming 
supramolecular hydrogel (Figure 3.5) based on the interaction of hyaluronic acid 
modified by CB[6] and alkylammonium ions 1,6-diaminohexane (DAH) or spermine 
(SPM). Initial studies demonstrated the rapid formation of a hydrogel upon mixing of 
CB[6]-HA with either DAH-HA or SPM-HA, though SPM-HA hydrogels exhibited 
significant toxicity toward fibroblasts in culture. In contrast, DAH-HA hydrogels exhibited 
good cytocompatibility and fibroblast proliferation was observed when hydrogels 
included the cell adhesive RGD sequence which was modularly included by guest-host 
interaction through preparation and addition of c(RGDyK)-CB[6].86 Building upon this 
work, they utilized the materials as a platform for the delivery of engineered 
mesenchymal stem cells (eMSCs) for suppression of tumor growth.121  The authors 
engineered MSCs to produce interleukin-12 (IL-12) through adenoviral transfection and 
demonstrated increased IL-12 production by hydrogel inclusion of retinoic acid (RA, 
hydrolytically bound to HA) and CB[6] conjugated dexamethasone (Dexa-CB[6], guest-
host bound). Assessment of enhanced green fluorescent protein (EGFP) expression in a 
subcutaneous injection model demonstrated cell retention and continued protein 
expression beyond 60 days, greater than three-fold longer than control hydrogels. 
Delivery of IL-12 producing eMSCs in a subcutaneous murine melanoma model was 
successful in retarding tumor growth and enhancing survival outcomes. Importantly, this 
 53	  
effect was enriched by inclusion of Dexa-CB[6] and RA, demonstrating the utility of 
supramolecular drug inclusion. 
While these studies by the Kim group have utilized sequential injection of the 
hydrogel precursors and in situ hydrogel formation, such approaches may be enhanced 
by a priori hydrogel formation in the presence of cells and subsequent shear-thinning 
delivery. Indeed, numerous shear-thinning hydrogel systems have increased delivery 
efficiency both by increasing cell viability and retention at the target site. Toward these 
efforts, the use of shear-thinning hydrogels based on CD-HA and Ad-HA, previously 
discussed, have been used to encapsulate and deliver endothelial progenitor cells 
(EPCs) to myocardial infarct tissue in rodents. Results demonstrated enhanced 
engraftment of the EPCs with hydrogel delivery (via constitutive GFP expression) at 1 
week post-injection when compared to injection of suspended EPC controls. The cell-
hydrogel therapy likewise resulted in enhanced vasculogenesis and contractile function 
when compared to controls of saline, EPC suspension, and hydrogel alone injections.122 
While results from such studies are promising, there is still much work to be done to 
optimize injection conditions of guest-host systems to make certain that viable cells are 
being delivered.  However, it is known that guest-host type hydrogels exhibit 
characteristic shear-thinning and shear-banding, similar to other supramolecular 
hydrogels where such studies have been performed. For example, in alternative 
supramolecular systems such as in β-hairpin peptide hydrogels, shear-thinning behavior 
resulted in plug-flow through cylindrical channels (mimicking injection through a needle 
or catheter), which reduced exposure of encapsulated cells to shear stresses and 
increased viability.123 Continuation of this work in loosely crosslinked alginate hydrogels 
has highlighted the importance of extensional flow, such as near entrance to the syringe 
needle, as a primary cause of acute cell death.The124 Extension of these studies toward 
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direct assembling guest-host hydrogels is essential toward understanding cell viability 
with respect to clinical applications of cell delivery. 
 
Figure 3.5. Schematic representation of in situ supramolecular hydrogel 
formation. Schematic of cell encapsulation (A), through mixing of cucurbit[6]uril-
conjugated hyaluronic acid (CB[6]-HA) and polyamine-conjugated HA (PA-HA) and 
subsequent modular modification with various CB[6] bound tags. The chemical 
structures (B) of CB[6] and PAs of diaminohexane (DAH) and spermine (SPM). Adapted 
from Sun et al. 83 
 
 
3.4. CONCLUSIONS  
Supramolecular guest-host chemistry has made great strides over the past 
decades since formalization of synthetic methods for their production and subsequent 
polymer modifications. Particularly in the field of bioengineering, these unique 
chemistries have shown great potential toward numerous applications. Arguably, the 
most advanced of these is therapeutic delivery, where the use of cavitands (cyclodextrin 
in particular) to enhance solubility and bioavailability of pharmaceutical drugs has 
become common practice. However, the capacity to harness these interactions for drug 
delivery systems (i.e. nanotherapeutics, drug-eluting coatings, and bioresponsive 
materials) currently remains primarily limited to basic research. Similar to alternative 
methods of now conventional delivery, such as liposomal formulation of 
chemotherapeutics, these methods hold promise as a means to revolutionize the 
pharmaceutical industry; though, their development to industrial scale and market 
approval remains a challenge.  
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At a more basic level, the use of guest-host materials as injectable therapeutics 
is of great interest to the medical community. Such material systems perpetuate 
numerous applications, including the local delivery of biomolecular therapeutics via 
diffusion and the supramolecularly controlled delivery of small molecules or suitably 
modified biomolecules. The use of such materials may also be of interest in tissue 
bulking applications (e.g., dermal fillers, regenerative scaffolds) and therapeutic cell 
delivery. However, the investigation of these important material systems and 
applications is mainly limited to in vitro investigation, with exceedingly few examples 
demonstrating in vivo efficacy. Further investigation of the in vivo material properties is 
needed to develop an understanding of material degradation, mechanics, and 
therapeutic elution. Similarly, the biological response to guest-host materials, including 
macrophage recruitment and long-term fibrotic encapsulation remains almost wholly 
unexamined. Further understanding of these systems in a functional, biological setting is 
a needed priority in the field.  
Finally, with respect to basic biological understanding—guest-host assembly offers a 
unique platform for investigation of cell behavior in response to substrates that mimic 
aspects of the dynamic ECM. This is embodied in the capacity to dynamically alter cell 
culture substrates, including to mimic features such as adhesion ligand mobility and 
substrate viscoelasticity in an attempt to represent more biomimetic cellular 
environments. Toward the applications discussed herein, understanding of the 
underlying chemical processes and polymer physics are of utmost importance, as they 
ultimately control the bulk material properties to enable dynamic, tunable, and 
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SUSTAINED SMALL MOLECULE DELIVERY FROM SUPRAMOLECULAR 




Mealy JE, Rodell CB, Burdick JA. Sustained small molecule delivery from injectable 
hyaluronic acid hydrogels through host–guest mediated retention. Journal of Materials 




Towards the development of translational, multifaceted strategies for treating 
disease, self-assembled hydrogels provide unique properties to deliver therapeutics 
(e.g., cells, drugs) to tissues. Self-assembly, driven through non-covalent interactions, 
may impart shear-thinning and self-healing properties to hydrogels, which allows direct 
injection into tissues. A number of non-covalent interactions have been investigated to 
form self-assembled hydrogels, including hydrophobic interactions or guest-host 
assembly of macrocycles such as cucurbiturils and cyclodextrins (CDs).1-3  
CDs are cyclic macromolecules formed from 6, 7, or 8 α-D-glucopyranoside 
units, termed α-, β-, and γ-CD respectively. As a strategy for self-assembly, these 
molecular interactions have been employed to form hydrogels between polymers 
modified with β-CD and adamantane (Ad), α-CD and PEG, and β-CD and azobenzene, 
among other polymer systems.3-5 These self-assembled hydrogels have been used 
towards a number of biomedical therapies, including mechanical interventions, cell 
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delivery, and sustained therapeutic release.6-9 CD guest-host chemistry has previously 
been used in the design of drug delivery systems. Notably, the Davis group has 
developed cationic CD polymers that ionically complex with nucleic acids to form 
nanoparticles, that may be functionalized with targeting ligands via Ad interactions to 
promote receptor-mediated endocytosis.10 Regarding sustained release, self-assembled 
hydrogels provide easily injectable depots of therapeutics; however, their investigation 
as drug delivery systems has largely been focused on macromolecules where release is 
governed through network properties. Despite recent advances in supramolecular 
systems, few supramolecular hydrogels have been investigated for small molecule 
release, due to difficulties associated with using these traditional mechanisms (e.g. 
matrix erosion, control of mesh size) to sustain the release of small molecules. 
Small molecule therapeutics are potent drugs that can be used in such strategies 
as chemotherapy or the inhibition of pathologic matrix metalloproteinase (MMP) activity, 
where there is a need for systems that permit localized and sustained therapeutic 
delivery.11 Due to the highly hydrated nature of hydrogels and their large mesh size, 
most small molecules will diffuse out rapidly in a matter of hours, which is often too fast 
to provide sustained therapeutic effects.  To address this challenge, strategies using 
composite systems of hydrogels and hydrophobic micro/nanoparticles or covalent 
conjugation of drugs to polymer backbones have been developed to provide sustained 
small molecule release.12 While these strategies are effective, they require added 
complexity in hierarchical formulation or offer regulatory translational limitations by 
modifying drug molecules. A third strategy that may be used to sustain small molecule 
release is to engineer non-covalent affinity between small molecules and polymers to 
increase retention time. Hydrogels using affinity mediated sustained release have 
recently been developed leveraging interactions between therapeutic peptides or 
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hydrophobic molecules and polypeptide-based hydrogels, as well as between 
macrocycle hosts and guest ligands.7,13,14 
CDs have remarkable affinity for a wide variety of small molecule guests, which 
has led to the use of CDs as excipients in a number of small molecule 
pharmaceuticals.15,16 In addition, these guest-host interactions have been leveraged to 
increase molecule retention within covalently crosslinked hydrogels.14,17-20 In one 
example, antibiotic release was sustained for ~10 days from covalently crosslinked 
polyurethane hydrogels of β-CD and multivalent isocyanates that were used to coat 
metal screws and polymer meshes.14,21 β-CD also forms inclusion complexes with a wide 
variety of other molecules, including chemotherapeutics such as doxorubicin, MMP 
inhibitors such as doxycycline, and even aromatic amino acids such as tryptophan.22-26 
However, β-CD inclusion complexes have not yet been leveraged to provide sustained 
small molecule release from hydrogels formed via supramolecular self-assembly. 
 Recently, our group developed a two component supramolecular hydrogel 
formed from hyaluronic acid (HA) modified with Ad (Ad-HA) and HA modified with β-CD 
(CD-HA).3 HA is a natural component of the extracellular matrix, which interacts with cell 
surface receptors and can even provide stem cell recruitment.27,28 We hypothesized that 
alterations in CD content and payload affinity for CD would alter the release of molecules 
from hydrogels (Figure 4.1). Such a system combines the unique shear-thinning and 
self-healing properties previously reported in these hydrogels with the unique guest-host 
inclusion capability of β-CD for a number of small molecule drugs.  
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Figure 4.1. Scheme for tuning release of small molecules from drug loaded 
supramolecular hydrogels. Ad-HA and CD-HA macromers were synthesized and 
evaluated for functionalization (x/[x+y]) using 1H-NMR. Macromers were dissolved in 
solutions containing varying drugs (green = high affinity for CD, red = low affinity for CD) 
and combined in varying ratios (Ad:CD) to produce bulk hydrogels. Release kinetics 
were tuned by varying the CD content available for drug binding or by altering the affinity 




Sodium hyaluronic acid (HA, 90kDa) was purchased from Lifecore (Chaska, MN). 
β-cyclodextrin (CD), 1-adamantane acetic acid, and hexanediamine (HDA) were 
purchased from TCI America (Portland, OR). Fluorenylmethyloxycarbonyl (FMOC) 
protected amino acids and (1H-Benzotriazol-1-yloxy)(dimethylamino)-N,N-
dimethylmethaniminium hexafluorophosphate (HBTU) were purchased from 





4.2.2. MACROMER SYNTHESIS 
Ad-HA was synthesized according to previously reported protocols.3 Briefly, HA 
was first converted to a tetrabutylammonium salt (HA-TBA) through the use of an ion 
exchange resin (Dowex 50Wx4). HA was dissolved in DI water at 3 wt% and mixed with 
the resin for 4 h to allow for ion exchange. The resulting solution was filtered, neutralized 
with tetrabutylammonium hydroxide, frozen, and lyophilized to produce the HA-TBA salt. 
To synthesize Ad-HA, HA-TBA, 4-methylaminepyridine, di-tertbutyl dicarbonate and Ad 
were then dissolved using dimethyl sulfoxide (DMSO) and allowed to react for 20 h at 45 
°C under nitrogen. The resulting Ad-HA product was then purified by dialysis against DI 
water for 3 days, precipitated in acetone, and then further dialyzed against DI water for a 
total of 2 weeks. The aqueous polymer solution was then frozen, lyophilized, and 
analyzed for purity and percent modification using 1H-NMR (DMX 360, Bruker, Billerica, 
MA).  All Ad-HA used in this study had ~25 % of HA repeat units modified with Ad 
groups (Figure 4.2). 
To facilitate conjugation to HA, β-CD was aminated using an HDA linker. First, β-
CD was tosylated through the reaction of p-toluenesulfonyl chloride and β-CD in 
aqueous solution. Sodium hydroxide (3 mol NaOH/ mol CD) was added dropwise to the 
solution and stirred for 30 min at room temperature. Next, ammonium chloride was 
added to adjust the pH to ~8.5 and precipitate the β-CD tosylate. β-CD tosylate was 
repeatedly washed in water and acetone and then dried under vacuum to use in the 
amination reaction. A 2-neck flask was charged with β-CD tosylate, HDA, and DMF. The 
flask was connected to a condenser, purged by nitrogen, and reacted for 16 h at 80 °C. 
CD-HDA was purified by repeated washes with acetone and diethyl ether to yield 
aminated β-CD (CD-HDA). To form CD-HA, HA-TBA, CD-HDA, and (benzotriazol-1-
ylozy)tris(dimethylamino)phosphonium hexafluorophosphate were dissolved in DMSO in 
a round bottom flask. The reaction was allowed to proceed for 3 h at room temperature. 
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CD-HA was then purified by dialysis against water for 2 weeks, frozen, lyophilized, and 
characterized using 1H-NMR. CD-HA used in this study was modified at ~35 % of HA 
repeat units for calorimetry experiments and ~25 % for all other experiments (Figure 
4.2). 
Methacrylated HA (MeHA) was synthesized according to previously reported 
protocols.29 Briefly, sodium HA was dissolved in DI water and methacrylic anhydride was 
added incrementally to the solution, while maintaining the pH between 7.5 - 8.5 for 5 h. 
The solution was then dialyzed extensively against DI water, frozen, lyophilized, and 
characterized using 1H-NMR. MeHA used in this study was modified at ~30 % of HA 
repeat units (Figure 4.2).   
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Figure 4.2. NMR spectra for various modifications of HA. 1H-NMR for CD-HA (a), 
Ad-HA (b), and MeHA (c). 
 
4.2.3. PEPTIDE SYNTHESIS 
Peptides were synthesized using standard solid phase synthesis on a solid 
phase peptide synthesizer (PS3, Protein Technologies Inc., Tuscon, AZ). Two 





were synthesized as model drugs that have a high or low affinity for β-CD, respectively. 
Peptides were synthesized on a glycinol 2-chlorotrityl resin and with FMOC protected 
amino acids. Peptides were cleaved in a mixture of trifluoroacetic acid, triisopropylsilane, 
and water (95:2.5:2.5) and then purified through precipitation in cold diethylether. Solid 
peptides were dissolved in DI water, frozen, and lyophilized. Peptide purity and 
sequence were confirmed using MALDI-TOF spectroscopy (Multiflex, Bruker, Billerica, 
MA). Masses for both 3W (expected 1549.6, m/z 1571.8, corresponding to a complex 
with Na ion) and NoW (expected 1162.1, m/z 1162.6) confirmed successful peptide 
synthesis. 
 
4.2.4. HYDROGEL PREPARATION 
Hydrogels were prepared by first dissolving CD-HA and Ad-HA in phosphate 
buffered saline (PBS) or PBS containing drug overnight at room temperature. The CD-
HA and Ad-HA solutions were mixed to induce gelation. For notation, hydrogels are 
referred to as x:y (z wt%) hydrogels, with x:y referring to the Ad:CD stoichiometric ratio 
within a given hydrogel, and z wt% referring to the total macromer weight percent of the 
hydrogel. All guest-host hydrogels were made using 25 % modified CD-HA and 25 % 
modified Ad-HA. 
MeHA hydrogels were formed through a photoinitiated radical polymerization of a 
macromer solution. MeHA at 7.8 wt% macromer concentration was dissolved in PBS 
containing fluorescent peptides and 0.05 wt% I2959 photoinitiator. MeHA macromer 
solution was then stored under nitrogen and polymerized using UV light at 10 mW/cm2 





4.2.5. ISOTHERMAL TITRATION CALORIMETRY 
Isothermal titration calorimetry (ITC) was performed using a low volume 
isothermal titration calorimeter (Microcal iTC200, Worcestershire, UK). Briefly, aqueous 
polymer solutions at 1 mg/mL and 0.468 mg/mL for CD-HA and HA, respectively, were 
titrated in 2 µL aliquots to a thermal cell filled with 200 µL of tryptophan at 40 µM. 
Differential power was recorded between the sample cell and a reference cell containing 
MiliQ water at a constant temperature of 25 °C. Baseline titrations of polymer solution 
into MilliQ water were subtracted in order to remove heats of dilution associated with 
polymer solution injection. The resulting isotherms were analyzed with Origin 7 software 
according to a one-binding site fit to determine association constants. In order to reduce 
errors associated with fitting multiple parameters (K, ΔH, n), stoichiometry was pre-
defined according to CD modification determined through 1H-NMR. 
 
4.2.6. RHEOLOGY 
Hydrogel mechanics were assessed using a stress-controlled rheometer 
(AR2000, TA Instruments, New Castle, DE). Oscillatory time sweeps were conducted at 
0.1, 1, and 10 Hz at 1% strain. Additionally, oscillatory frequency sweeps were 
performed between 0.01 Hz and 100 Hz at 1 % strain. Finally, to simulate injection, 
hydrogels underwent a cycle of strain between 1 % (low strain) and 500 % (high strain) 
at 1 Hz. Storage and loss moduli were analyzed for both drug loaded and unloaded 
hydrogels.  
 
4.2.7. FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING 
Fluorescence recovery after photobleaching (FRAP) experiments were 
conducted on a confocal microscope (TCS SP5, Leica, Wetzlar, Germany). In each 
experiment, 20 µL hydrogels were placed on glass slides and covered with a glass cover 
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slip. The 488 nm line of an argon laser was set to 50 % power and all images were taken 
using the 10x objective with the pinhole fully opened. Pre-bleach images were recorded 
over 2 seconds using 0.1 % transmission. A 30 µm diameter region was then bleached 
for 4 seconds using 100 % transmission. Post-bleach images were then recorded with 
the laser returned to 0.1 % transmission for 230 s of recovery. Data was analyzed using 
a custom MATLAB script that fit recovery profiles using nonlinear least squares 
regression to the Soumpasis equation: 
 
where 𝐹 𝑡   is the normalized fluorescence recovery profile, 𝑘  is the mobile fraction,  
represents the characteristic diffusion time (s), 𝑡  represents time (s), and 𝐼!  and 𝐼!  are 
zero and first order modified Bessel functions of the first kind.30 Effective diffusivities 




where 𝐷!""  is the effective diffusivity (µm2 s-1) and 𝑤 represents the bleach spot radius 
(µm). This protocol was adapted from previous work conducting similar analyses.31  
 
4.2.8. MOLECULE RELEASE PROFILES 
Release assays were conducted in custom made acrylic erosion cells. Erosion 
cells were fabricated with a 4.3 mm diameter hydrogel chamber overlaid with a 1.6 cm 
diameter supernatant chamber, each chamber having depths of 7 mm and 10 mm, 
respectively. 30 µL of the hydrogel was deposited in the chamber, the chamber was 





































mL of PBS. Once loaded, erosion cells were stored in an incubator at 37 °C. 
Supernatant was collected at regular intervals and replaced with fresh PBS. Molecule 
release was determined with a plate reader (Infinite M200, Tecan, Männedorf, 
Switzerland). FITC labeled peptides were analyzed using 495/525 nm excitation 
emission, doxycycline was analyzed using 350 nm absorbance, and doxorubicin was 
analyzed using 480/590 nm excitation/emission. At the end of each assay, any 
remaining hydrogel was collected along with supernatant and disassociated with addition 
of 5 mg/mL Ad solution in DMSO to obtain final fluorescence/absorbance readings. 
Fluorescence and absorbance values were then compared to standard curves to 
determine total molecule release. 
 
4.2.9. STATISTICAL ANALYSIS 
Affinity measurements are presented as an average of affinity constants 
determined from n = 3 isotherms per trial. Mechanical measurements are presented as 
an average and standard deviation for n = 3 samples. FRAP measurements were 
conducted for n = 4 recovery profiles, and presented as average effective diffusivities 
and standard deviations. Release profiles are presented as average cumulative percent 
release and standard deviation of cumulative release for n = 4 samples. Statistical 
analyses on ITC and rheology measurements were conducted using two-tailed student t 
tests. One-way ANOVA with post-hoc Tukey’s Honestly Significant Difference testing 





4.3. RESULTS AND DISCUSSION 
4.3.1. SMALL MOLECULE BINDING TO HA 
HA was successfully functionalized with CD to produce CD-HA, with ~35 % of HA 
repeat units modified.  It was first investigated whether CD modification of HA could 
increase the polymer affinity for small molecules, using ITC. As a representative small 
molecule, L-tryptophan was used to investigate this interaction, due to its aromatic 
structure, hydrophobic nature, and previous investigation of affinity with CD.15,24,26 
Additionally, as a natural amino acid, L-tryptophan presents an interesting binding target, 
as it allows for peptide design with natural compounds that may promote polymer 
affinity.  
Isotherms produced by CD-HA and unmodified HA titrations were vastly different 
(Figure 4.3 a,b). CD-HA produced a distinct exothermic reaction upon mixing with 
tryptophan in the sample cell, while unmodified HA remained at near baseline levels for 
all injections. Isotherms were quantitatively analyzed in Origin 7 software by a one-
binding site model fit to determine the apparent association constant (KA) between the 
polymer and tryptophan. The binding site stoichiometry value (n) was set to 0.35 to 
account for CD modification as determined by 1H-NMR and to reduce error associated 
with fitting multiple parameters. Fits for isotherms of CD-HA and tryptophan produced an 
average KA of 1.6×104 ± 2.9×103 M-1. While this value is slightly higher than previously 
reported values for this interaction, the increase may be attributed to changes in CD 
chemistry upon conjugation to HA, as it has been shown that these changes can alter 
binding affinities to tryptophan.26 Accurate values for KA were not attainable in 
unmodified HA isotherms due to high error associated with parameters obtained from 
fits, which is attributed to randomly scattered integrated heat values resulting from near 
baseline heat changes for all injections. Taken together, these data suggest that 
modification of HA with CD provides a multiple orders of magnitude increase in affinity 
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for tryptophan. Since the cyclic domains such as the indole moiety found in tryptophan 
are found in many pharmacologic small molecules, this increase in affinity suggests that 
HA modification would allow increased affinity for many small molecules.32  
 
Figure 4.3. Isothermal titration calorimetry for HA binding to tryptophan. Solutions 
of HA (either unmodified or modified with CD) dissolved in MilliQ water were titrated into 
40 µM tryptophan in MilliQ water. Baseline isotherms of modified or unmodified HA into 
water were subtracted to account for heats of dissolution. Representative isotherms and 
chemical structures of binding components are shown for (a) unmodified HA binding to 
tryptophan or (b) CD-HA binding to tryptophan.  
 
4.3.2. EFFECT OF DRUG LOADING ON HYDROGEL MECHANICS 
HA was also successfully modified with Ad groups to form Ad-HA. Gelation 


























































through guest-host interactions of Ad and CD groups.  Since incorporated small 
molecules also complex with CD, it is important to understand the competitive effect of 
drug loading on hydrogel mechanics. As a model drug, a peptide modified with 
tryptophan and FITC (termed 3W, due to 3 tryptophan residues per peptide) was loaded 
(1 mg/mL) into 1:1 (5 wt%) hydrogels. This notation of the form ‘x:y (z wt%)’ refers to the 
molar ratio of Ad:CD in the hydrogel (x:y) and the total polymer weight percent in the 
hydrogel (z).  This formulation was selected for mechanical testing since it would have 
the greatest chance to reduce hydrogel mechanics with drug loading, as the Ad:CD ratio 
is 1:1. The loading concentration for 3W of 1 mg/mL is at the peptide solubility limit and 
is ~5 % of the total CD content in the hydrogel. Furthermore, this concentration is orders 
of magnitude higher than loading concentrations used in subsequent release assays.  
Please note that the peptide was not designed for any bioactivity, but rather for use as a 
model molecule to investigate the influence of hydrogel design on diffusivity and release. 
To examine the effect of molecule incorporation on hydrogel mechanical 
properties, frequency response profiles for G’, G”, and tan(δ) were obtained. Hydrogels 
displayed frequency responsive behaviors that are characteristic of self-assembling, two-
component systems (Figure 4.4a). Both molecule-loaded and unloaded hydrogels 
exhibited similar frequency response profiles for these parameters, showing qualitative 
similarity in mechanics. Time sweeps were conducted to assess differences between 
these two groups in shear and loss moduli at 0.1 Hz, 1 Hz, and 10 Hz. Both formulations 
displayed frequency responsive increases in storage moduli (Figure 4.4b) and loss 
moduli (Figure 4.4c) and there were no significant differences in either storage or loss 
moduli (p > 0.05) between the formulations. One explanation for the lack of difference in 
bulk mechanics with and without encapsulated small molecules is the relative difference 
in affinity of tryptophan for CD as compared to AD. The association constant for the Ad-
CD complex has been reported to be as high as 105 M-1, orders of magnitude higher 
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than previous reports for tryptophan-CD, suggesting that there would be minimal 
competition between the two.15,26 Considering that a wide variety of small molecules 
complex with CD on the same order of magnitude as tryptophan, it is unlikely that 
loading of therapeutics would compete with the formation of the Ad-CD complex and 
cause a decrease in hydrogel mechanics.15 
Finally, loaded hydrogels were subjected to a cyclic strain protocol, whereby 
hydrogels were placed under cycles of high and low oscillatory strain to simulate 
conditions during injection and recovery after injection. This technique has been used 
previously to examine network disassembly and reassembly in self-assembling systems 
from a mechanical perspective.33-36 Hydrogels showed a rapid decrease in storage 
modulus under high strain, indicating a reduction in elastic properties and a more fluid-
like behavior, as well as a rapid recovery of the storage modulus under low strain, 
suggesting a return to a more elastic, gel-like state (Figure 4.4d). Hydrogels loaded with 
the peptide rapidly assembled after injection, indicating that there would be minimal 
extravasation during administration (Figure 4.5). These characteristics are important in 
the development of translational therapies, so that both hydrogel and drugs may be 
precisely localized.  This aspect can be challenging with alternative injectable hydrogels 
that covalently crosslink at the injection site, as hydrogels may clog the delivery device if 
gelation occurs too quickly or may diffuse from the injection site prior to gelation if 
gelation is too slow.6  
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Figure 4.4. Comparison of mechanical properties in unloaded and drug loaded 
(3W peptide, 1mg/mL) hydrogels (1:1 (5 wt%)). (a) Representative frequency sweeps 
showing G’ (unloaded=blue solid circles, loaded=red solid squares), G” (unloaded=blue 
open circles, loaded=red open squares), and tan(δ) (unloaded=black open circles, 
loaded=black crossed squares). (b) Average G’ values for time sweeps for unloaded 
(blue) and loaded (red) hydrogels for 0.1Hz, 1Hz, and 10Hz frequencies. (c) 
Representative cyclic strain experiment showing G’ (red solid line), G” (red dashed line), 
and strain (black dotted line) for loaded hydrogels undergoing cycles of low and high 
strains.  
 
Figure 4.5. Hydrogel injection. Injection of a 1:2 (7.8 wt%) hydrogel loaded with 100 

















4.3.3. EFFECT OF MOLECULE AND HYDROGEL PARAMETERS ON DRUG 
MOBILITY  
Fluorescence recovery after photobleaching experiments were used to assess 
encapsulated molecule mobility within hydrogels as a function of hydrogel parameters 
and molecule interaction with CD. Using this technique, small regions of hydrogels 
loaded with mobile fluorescent payloads were bleached with a high intensity laser. The 
recovery of fluorescence due to diffusion of unbleached molecules into the region was 
then monitored and quantified to determine the diffusivity of the fluorescent payload 
within the hydrogel. Two fluorescently labeled peptides were used in these experiments: 
a high affinity peptide for CD (3W), as well as a lower affinity peptide, in which the 
tryptophan residues were replaced with glycine (NoW, GKGEGKGE-FITC). These 
peptides were used as model drugs to represent payloads of varying molecular affinities, 
and were loaded into hydrogels at 100 µM.  
To assess the influence of hydrogel formulation on molecule mobility, CD content 
within hydrogels was altered by increasing the overall CD-HA concentration (1:1 (5 
wt%), 1:2 (7.8 wt%), and 1:3 (10.5 wt%)). As CD concentration increased, the effective 
diffusivity of the 3W peptide significantly decreased within the hydrogel (Figure 4.6a). 
These data suggest that the increase in CD-HA content does reduce peptide mobility 
within the hydrogel. To address the potential confounding effects that an increase in total 
macromer concentration may have on mobility, an additional formulation at a 1:2 Ad:CD 
ratio was compared to the 1:1 Ad:CD ratio, with both hydrogels at 5 wt%. The 1:2 Ad:CD 
formulation showed significantly lower effective diffusivities than the 1:1, despite 
maintaining a similar total macromer concentration of 5 wt% (Figure 4.6b). This 
comparison suggests that the CD-HA component itself is a significant contributor to 
molecule diffusivity, which is supported by the binding affinity results quantified by ITC 
analysis.  
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To further investigate this affinity mediated reduction in mobility, we explored the 
effect of removing the tryptophan residue from the 3W peptide by using the NoW 
peptide. A 1:2 (7.8 wt%) hydrogel was loaded with 100 µM NoW peptide and compared 
to a similarly formulated hydrogel with 100 µM 3W peptide.   It was observed that the 
NoW peptide had significantly higher diffusivity in the same hydrogel when compared to 
the 3W for the given 100 µM concentration (Figure 4.6c). These results can be 
observed visually in Figure 4.6d. Both peptides were bleached with similar efficiencies 
(1 s), but show differences in recovery profiles (3 s and 8 s) until both reach almost full 
recovery (30 s). The influence of peptide chemistry on mobility further implies the 
importance of CD affinity in controlling peptide mobility in these hydrogels.  
 
Figure 4.6. Fluorescence recovery after photobleaching experiments. Hydrogels 
loaded with fluorescent peptides were assessed with FRAP analysis to determine 
payload mobility within the hydrogel. Diffusivity of fluorescent peptide payloads in 
hydrogels was assessed with changes in (a) CD-HA wt%, (b) Ad:CD ratio at a total 
polymer concentration of 5 wt%, and (c) payload chemistry (3W versus NoW). (d) 
























































4.3.4. EFFECT OF MOLECULE AND HYDROGEL PARAMETERS ON BULK 
RELEASE PROFILES 
Towards investigating the small molecule sustained release properties of these 
hydrogels, we next investigated the effect that both hydrogel and payload parameters 
have on bulk release profiles. As in the FRAP experiments, groups were selected to 
compare the effects of increasing CD-HA concentration, increasing the Ad:CD ratio for a 
given total weight percent, and changing the relative affinity of a fluorescently labeled 
payload. In order to provide a contrast to this affinity-based interaction, release from a 
covalently crosslinked hydrogel with no CD content was examined. MeHA hydrogels 
containing no CD content were formed through the photoinitated polymerization of 30 % 
modified MeHA at 7.8 wt% and containing 100 µM of the 3W peptide. Peptide release 
into PBS was examined over 8 days. This profile (Figure 4.7) showed ~90 % release in 
the first 24 h and exemplifies the issues with sustaining small molecule release from 
traditional swollen hydrogels.  
 
Figure 4.7. Cumulative 3W release. 3W release from covalently crosslinked hydrogel 
containing no cyclodextrin (MeHA). 
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Towards investigating the cyclodextrin retentive effect in our hydrogels, several 
formulations were explored. All supramolecular hydrogels discussed here were loaded 
with 100 µM of peptide. This represents approximately a 1:100 ratio of peptide to CD 
available for binding (i.e., CD that has not been paired with Ad) in a 1:2 (7.8 wt%) 
system. This ratio is consistent with values investigated in previous modeling studies 
investigating affinity mechanisms in drug release.37 The effect of increasing CD-HA 
macromer concentration was assessed in these hydrogels by conducting release 
experiments on a 1:1 (5 wt%), 1:2  (7.8 wt%), and 1:3 (10.5 wt%) hydrogels. Results of 
these systems are shown in Figure 4.8a. Analogous to trends observed in molecule 
diffusivity from FRAP studies, increasing the CD-HA content of these hydrogels 
produced slower bulk release kinetics. In the first 24 h, ~70 %, ~35 % and ~20 % of the 
initial payload was released for the 1:1 Ad:CD, 1:2 Ad:CD, and 1:3 Ad:CD systems, 
respectively. These results are markedly improved over the MeHA system, and show the 
increased ability of mismatched systems to sustain the release of small molecule 
payloads. Furthermore, even matched systems, where there is an equal molar ratio of 
Ad and CD, present some sustained release capabilities. This is likely due to spatial 
limitations in the network that prohibit complete consumption of CD by Ad guests, 
leaving the remaining CD available to bind to drugs. It should also be noted that only 
marginal improvements in sustained release were observed when shifting from 1:2 to 1:3 
Ad:CD hydrogels. Likely this is due to an upper limit on retentive effects that can be 
achieved through CD-peptide guest-host interactions for this particular payload and 
concentration. These materials also displayed moderate erosion during the three-week 
assay, and are comparable to our previous reports on the degradation of this material 
(Figure 4.9). 3 
A comparison of release profiles between a 1:1 (5 wt%) to a 1:2 (5 wt%) hydrogel 
(Figure 4.8b) further indicates that the sustained properties are a result of CD content 
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within the hydrogel. A mismatched system of the same macromer concentration 
produced slower sustained release profiles, which can be attributed to the increased 
amount of unbound CD available to bind and retain the peptide. Finally, the effect of 
varying peptide affinity on bulk release was investigated. Hydrogels were formulated at 
1:2 (7.8 wt%) and 100 µM concentration of either 3W or NoW peptide. Release over 21 
days was markedly slower for 3W when compared to the NoW peptide (Figure 4.8c). 
However, the NoW peptide still shows some degree of sustained release from these 
hydrogels, since CD binds with a number of small hydrophobic moieties such as the 
fluorescein dye on NoW. Release data of these peptides with varying structure further 
reinforces the importance of CD affinity in these systems. 
Overall, these release studies have elucidated a number of properties about 
these hydrogels and the release of small molecules. First, our self-assembled hydrogels 
provided sustained release of two different peptides for up to 3 weeks. This shows 
remarkable improvement over the capacity of traditional systems (i.e., hydrogels without 
a drug affinity component) to sustain the release of molecules of this size (Figure 4.7). 
These systems have tunable profiles that can be changed through a number of 
parameters. Engineering molecule affinity is one mechanism that can provide specific 
control of release profiles on a drug-to-drug basis. This is useful particularly in the 
delivery of peptide therapeutics, as these can be readily engineered with groups such as 
tryptophan that will promote the appropriate release profile. Finally, and most 
importantly, by varying the amount of CD-HA macromer in these hydrogels, the extent of 
molecule retention and subsequent release can be easily controlled. These multiple 




Figure 4.8. Release profiles of entrapped peptides. Hydrogels containing fluorescent 
peptides were injected in custom designed erosion cells and peptides released into PBS 
were quantified. Cumulative release profiles were determined in gels with changes in (a) 
CD-HA wt%, (b) Ad:CD ratio at total polymer concentration of 5 wt%, and (c) payload 
chemistry (3W versus NoW). Insets show an expanded view of time points collected 







Figure 4.9. Hydrogel degradation. Hydrogel erosion for matched and mismatched CD-
HA/Ad-HA systems. 
 
4.3.5. SUSTAINED RELEASE OF DOXYCYCLINE AND DOXORUBICIN 
To show the application of these systems towards small molecule 
pharmacologics, two clinically used small molecule therapeutics (i.e., DOX, DXY) were 
investigated. These drugs were selected as DOX is a chemotherapeutic that acts 
through intercalating with DNA and DXY has been investigated as an MMP inhibitor, 
both classes of drugs that benefit from localized delivery and both been shown 
previously to form complexes with CDs and their derivatives.22,25,38-40 Both the 1:1 (5 
wt%) and a 1:2 (7.8 wt%) hydrogel formulations were investigated for release, with drug 
loading at 1 mg/mL.  DOX release was sustained over the first 14 days of the study 
(Figure 4.10a). As observed with fluorescently labeled peptide substrates, increasing 
CD-HA content in DOX loaded hydrogels produced a similar reduction in release 
kinetics, particularly noticeable during the first week. DXY loaded hydrogels also showed 
similar trends to the DOX loaded systems (Figure 4.10b). The sustained release effect 
of increased CD-HA content was more pronounced in DXY release profiles, and this 
may be attributed to differences in CD affinity between DXY and DOX, which have been 
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reported at 503 M-1 and 297 M-1, respectively.22,41 Profiles for the 1:2 Ad:CD formulation 
for both drugs also indicate incomplete release of the encapsulated payload, with an 
increased fraction of drug retained in the hydrogel at the study endpoints. These data 
show the versatility of the presented hydrogel system in delivering a number of small 
molecules in a readily translatable manner. As injectable systems, hydrogels providing 
sustained release of either of these two molecules could find biomedical applications, 
such as in cancer therapies.39,42  Although the work here did not illustrate bioactivity of 
released drugs, we do not expect any comprised activity since we have not chemically 
modified the drugs and others have shown activity of molecules in delivery systems 
leveraging non-covalent inclusion complexes.43,44 
 
Figure 4.10. Release of doxorubicin (DOX) and doxycycline (DXY) from injectable 
hydrogels. Cumulative release of (a) DOX or (b) DXY for 1:1 (5 wt%) (red) or 1:2 (7.8 
wt%) (blue) formulations over 3 weeks. Insets show an expanded view of time points 
collected during the first 5 days. 
 
4.4. CONCLUSIONS 
Here, we have developed a physically assembled hydrogel system for the 
tunable and sustained release of small molecules using CD guest-host interactions. 
Modification of HA with CD increased affinity for model small molecules by multiple 
a b 
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orders of magnitude, and this affinity was leveraged to tune the release of peptide model 
drugs, as well as doxorubicin and doxycycline, from assembled hydrogels. Furthermore, 
hydrogel drug-loading had minimal effects on mechanics and allowed the hydrogels to 
retain their injectable and rapid self-assembly properties. Ultimately, the work presented 
in this paper shows a small molecule, controlled release system that is rapidly 
formulated, easily tuned, and avoids the potential challenges associated with other 
injectable delivery systems.  
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GUEST-HOST HYDROGELS FOR THE DELIVERY OF SMALL MOLECULE MMP 




Myocardial infarction (MI) is an occlusion of a coronary artery that results in an 
ischemic region within the myocardium.1 The heart then undergoes a series of events 
that can result in a loss of mechanical function and progression to long-term heart failure 
and mortality.2 Specifically, in the days to months after the initial infarction event, the 
heart undergoes structural changes, collectively known as left 
ventricular (LV) remodeling.3,4 Initiated by the loss of contractile cells and inflammation, 
the left ventricle ultimately dilates, the myocardial wall thins, and the infarct region 
expands and transitions to scar tissue.5-7 Currently, treatments for MI focus on initial 
tissue reperfusion and decreasing the work-load of the heart; however, few treatments 
actually address the underlying processes that drive the progression of LV remodeling.1 
A major biological process that contributes to LV remodeling is the maladaptive 
upregulation of matrix metalloproteinases (MMPs) - proteases that are responsible for 
degradation of the extracellular matrix (ECM).5,8,9 The role of MMPs in MI has been 
widely investigated over the past two decades and transgenic deletion of MMPs or 
systemic inhibition via pharmacologics have shown that MMPs play a key role in 
regulating LV remodeling, and ultimately, cardiac dysfunction.4,10-15 MMP upregulation is 
a result of early inflammation and altered activity of fibroblasts and other endogenous 
cells; while the purpose of this inflammatory response is to promote invasion of 
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macrophages to clear cellular debris and to induce new vasculature in the myocardium, 
the collateral damage on tissue mechanical properties significantly promotes adverse LV 
remodeling.5,6,9 MMP changes are largely localized to the infarcted tissue and are 
specific to a small subset of MMPs.14,16  
Endogenously, MMP activity is regulated through the activity of the four tissue 
inhibitors of matrix metalloproteinases (TIMPs). TIMPs undergo a significant down-
regulation in MI, concomitant with the aforementioned increase in MMP activity.14 
Furthermore, deletion of TIMP-3 in animal models increases LV remodeling and loss of 
cardiac function after an MI.17-19 As a means to replicate the function of TIMPs, 
numerous small molecule MMP inhibitors have been developed that have broad-
spectrum or targeted inhibition on a subset of MMPs. These molecules have faced 
challenges clinically, frequently producing off-target effects such as musculoskeletal 
syndrome (MSS) in patients enrolled in trials with systemic delivery of MMP inhibitors for 
indications such as cancer and arthritis.20-22 Due to these concerns, a clinical trial 
evaluating the inhibitor PG116800 for treatment of MI, PREMIER, ultimately reduced the 
dosing of the inhibitor from initially administered levels.20 While this new dose did not 
produce MSS, the drug failed to influence LV geometry and function, likely due to 
inadequate concentrations to achieve therapeutic efficacy.  
Biomaterials provide an opportunity to localize MMP inhibitors to the tissue of 
interest to avoid off-target issues, while maintaining high enough doses for efficacy.  For 
MI, hydrogels (water-swollen crosslinked polymer networks) are particularly appealing, 
due to their diverse properties and potential for injection into cardiac tissue, including 
through percutaneous routes.   Indeed, numerous hydrogels have already been injected 
into the myocardium after MI to impart mechanical stability to the remodeling tissue.23-27 
Additionally, hydrogels have been widely explored for local drug delivery, where the 
therapeutic is entrapped during gelation and then released based on diffusion and 
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degradation mechanisms.28,29 We previously used this approach to deliver 
exogenous TIMP-3 after MI and observed improvements with respect to remodeling and 
cardiac function, without spill-over to the circulation.23,30  
Beyond the delivery of TIMPs, there is great interest in the local delivery of small 
molecule MMP inhibitors, including those that showed promise but were not explored 
further due to concerns with systemic delivery.  One of these molecules is SD7300, an 
MMP inhibitor developed by Pfizer, that has shown potential in preclinical studies to 
provide improvements in cardiac outcomes after MI, but there are concerns with off-
target effects such as MSS.31 However, there are particular challenges to the delivery of 
small molecules from hydrogels, as their size leads to rapid diffusion from the network.28 
To address this, we describe here the development of an injectable hydrogel that 
sustains the release of SD7300, through interactions between the hydrogel and the drug.  
Further, we investigate delivery and efficacy in an ischemia/reperfusion model of MI in 
swine, including delayed percutaneous delivery.  
 
5.2. METHODS 
5.2.1. MACROMER SYNTHESIS 
All materials were purchased from Sigma-Aldrich unless otherwise indicated. 
Hyaluronic acid (HA) (74kDa, Lifecore) was first converted to a tetrabutylammonium salt 
(HA-TBA) through the use of an ion exchange resin (Dowex 50Wx4), where HA in 
deionized (DI) water was mixed with the resin for 4 h and the product was filtered, 
neutralized with tetrabutylammonium hydroxide (TBA), frozen, and lyophilized to 
produce the HA-TBA salt. Subsequent synthesis of adamantane modified HA (Ad-HA) 
and cyclodextrin modified HA (CD-HA) was conducted according to previously described 
protocols.32 HA-TBA, 4-methylaminepyridine, di-tertbutyl dicarbonate and adamantane 
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were dissolved in dimethyl sulfoxide (DMSO) and allowed to react for 20 h at 45 °C 
under nitrogen to produce Ad-HA, which was purified by dialysis against DI water for 3 
days, precipitated in acetone, and then further dialyzed against DI water for a total of 2 
weeks. The aqueous polymer solution was then frozen, lyophilized, and analyzed for 
purity and modification using 1H-NMR (DMX 360, Bruker, Billerica, MA).  All Ad-HA used 
in this study had ~25 % of HA repeat units modified with adamantane. 
To facilitate conjugation to HA, β-CD was aminated using a hexamethane 
diamine (HDA) linker, as described previously to yield aminated β-CD (CD-HDA).32 To 
form CD-HA, HA-TBA, CD-HDA, and (benzotriazol-1-
ylozy)tris(dimethylamino)phosphonium hexafluorophosphate were dissolved in DMSO in 
a round bottom flask. The reaction was allowed to proceed for 18 h at room temperature. 
CD-HA was then purified by dialysis against water for 2 weeks, frozen, lyophilized, and 
characterized using 1H-NMR. CD-HA used in this study was modified at ~35 % of HA. 
 
5.2.2. HYDROGEL FORMATION AND CHARACTERIZATION 
Hydrogels were prepared by first dissolving CD-HA and Ad-HA in phosphate 
buffered saline (PBS) or PBS containing the small molecule for encapsulation (i.e., 
SD7300, IR800) and the mixing for immediate gelation. Hydrogels of varying 
formulations were generated, containing the relative molar ratios of cyclodextrin to 
adamantane of 1:1, 2:1, and 3:1 at 6 wt% total macromer concentration. Hydrogels were 
characterized using a stress-controlled rheometer (AR2000, TA Instruments) fitted with a 
20 mm diameter cone (0.995° angle) and a 27 µm gap. Oscillatory time sweeps were 
conducted at 0.1, 1, and 10 Hz at 1% strain. Additionally, oscillatory frequency sweeps 
were performed between 0.01 Hz and 100 Hz at 1 % strain. Continuous flow 
experiments were conducted at shear rates ranging from 1 s-1 to 10 s-1. Injection force 
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testing was conducted using an Instron compressive testing apparatus with a 1 mL 
syringe and 21G needle, with extrusion rates conducted at 12, 30, and 60 mm/min..  
 
5.2.3. DRUG RELEASE AND ACTIVITY 
Release assays were conducted in custom made acrylic erosion cells. Erosion 
cells were fabricated with a 4.3 mm diameter hydrogel chamber overlaid with a 1.6 cm 
diameter supernatant chamber, each chamber having depths of 7 mm and 10 mm, 
respectively. 30 µL of the hydrogel was deposited in the chamber, the chamber was 
centrifuged to provide an even hydrogel surface, and the hydrogel was covered with 1 
mL of PBS. Once loaded, erosion cells were stored in an incubator at 37 °C. 
Supernatant was collected at regular intervals and replaced with fresh PBS. At the end 
of the study, any remaining hydrogel was collected along with supernatant and 
disassociated with addition of 5 mg/mL Ad solution in DMSO. 
Molecule release was determined with a plate reader (Infinite M200, Tecan). 
SD7300 content was measured at 270/304 nm excitation/emission and IR 800 was 
analyzed at 774/800 nm excitation/emission. Fluorescence and absorbance values were 
then compared to standard curves to determine total molecule release. The MMP-2 
inhibitory activity of hydrogel releasates was determined using a fluorogenic MMP-2 
activity assay. Briefly, rhMMP-2 was activated with 4-aminophenylmerucric acetate for 
1h at 37 °C. In a 96 well plate, 50 uL of MMP-2 solution was added to 40 uL of hydrogel 
releaseate and incubated for 1 h to allow for binding of SD-7300 to the active site of 
MMP-2. Finally, 10 uL of fluorogenic MMP substrate was added to each well, yielding 
final concentrations of 0.25 ng/µL MMP-2 and 20 µM fluorogenic substrate. Immediately 
after addition of the fluorogenic substrate, samples were read for a 5 min kinetic cycle 
with a plate reader at 320/405 nm. The slope of the initial linear portion of this curve was 
used as a metric for enzyme activity, and baseline values (i.e., fluorogenic substrate with 
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no MMP-2) were subtracted from data points, and values were subsequently normalized 
to samples containing no MMP-inhibitor.  
  
5.2.4. PORCINE MI MODEL 
Mature pigs (n=19) (Yorkshire, male, 15-20 kg) were administered amiodarone 
(200 mg PO) and aspirin (81 mg PO) for 3 days pre-operatively and a broad spectrum 
antibiotic (Draxxin, 2.5 mg/kg, IM) at least once pre-operatively. On the day of surgery, 
pigs were sedated (ketamine/acepromazine/atropine: 22/1.1/0.04 mg/kg IM, 
respectively), intubated, and then maintained on 1.5-2% isoflurane delivered in an 
oxygen/nitrous mixture (3:1 L/min, respectively). Buprenorphine (0.05 mg/kg IM) was 
administered as pre-surgery analgesia.  An intravenous infusion (via ear vein cannula) of 
Benadryl (25 mg) in conjunction with a continuous lidocaine infusion (4 mg/kg/hr) and 
lactated ringers solution (10 mL/kg/hr) was initiated. This anesthesia/premedication 
protocol prevented refractory arrhythmias during the IR protocol. 
The region encompassing the right femoral artery was prepared in a sterile 
fashion, the main branch of the femoral artery surgically exposed, and a catheter 
introducer (6F Input Introducer Sheath, Medtronic) positioned and stabilized in the 
artery. A bolus of heparin was administered (4000 units, IV) prior to placement of the 
guide catheter followed by an additional bolus every hour (1000 units, IV). Under 
fluoroscopic guidance (GE OEC 9600, UT), a coronary angiography catheter/launcher 
(5F Launcher guiding catheter .058" HSI, Medtronic) was placed in the left coronary 
ostia, and an angioplasty balloon catheter containing an injection lumen (3mm x 10mm 
Sprinter OTW balloon catheter, Medtronic) was positioned in the lower portion of the left 
anterior descending artery (LAD; as defined as 1cm below the First Diagonal). The LAD 
was occluded by balloon inflation (12 ATM balloon inflation pressure, Everest 30 
Disposable inflation device, Medtronic) and maintained for 90 minutes. 
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Prior to the initiation of the procedure, the pigs were randomly assigned, in a 
blinded fashion to the following groups: IR induction only (IR-only; n=8), IR-gel only (IR-
gel; n=4), or IR-gel containing SD7300 (IR-gel/7300; n=7). The balloon was then 
deflated and the catheter system disengaged and removed. The femoral artery was 
ligated and the incision closed. A transdermal fentanyl patch was placed for 3 days for 
post-operative analgesia.  
 
5.2.5. HYDROGEL INJECTIONS INTO PIGS 
To perform the MI injections, the pigs randomized to this protocol were returned 
to the cardiac surgical laboratory 3-5 days after MI, and anesthesia performed as 
described previously [ref]. A 1.5 cm incision was made at the right anterior sternal-costal 
cartilage junction, just superior to the xiphoid process.  A pediatric Finochietto retractor 
was placed and the anterior aspect of the LV containing the MI region exposed. The 
pericardium was incised, and the MI region constituting a ~3X3 cm area was visualized 
and the basal and apical borders of the MI identified.   
A preloaded syringe containing the hydrogel was connected to a 2”, 24 gauge 
needle (BD), and 9 injections of 100 uL volume each were placed in a equidistant 
diamond shape pattern within the MI region at a depth of 5 mm, forming clear solid gel 
pockets below the epicardial surface of the MI. At the conclusion of the injections, the 
incisions were closed without irrigation, and the total procedural time was 30±5 min. 
Only transient, non-sustained arrhythmias were encountered during the actual injections, 
and no other intra/post-operative complications were encountered. 
 To visualize hydrogel distribution, cardiac tissue (n=1) was explanted 
immediately after injections and imaged on a 9.4T MRI scanner (Siemens). A T2-
weighted turbo spin echo with the following parameters was used to acquire segments 
for 3D reconstruction: matrix size 320x256x65, voxel size = 0.3125x0.3125x1.0 mm3, 
 107	  
repetition time = 1128 ms, echo time = 71 ms, 4 signal averages. Hydrogel pockets were 
visualized using 3D reconstructions of myocardial segments in ITK-SNAP2. 
To track small molecule release in vivo, IR800 dye (Licore) was used as a 
representative small molecule and loaded into guest-host hydrogels at a concentration of 
1 mg/mL hydrogel and injected into MI regions as described above. Sacrifice (n=1) 
occurred 2 days after injection, at which point the myocardium was sectioned into 0.25 
cm thick, short-axis sections and imaged using an IVIS transdermal imaging system and 
presented as overlay images with bright field images of the myocardial section.  
 
5.2.6. FUNCTIONAL ANALYSIS 
Baseline echocardiography prior to IR induction, as well as 14 and 28 days post-
IR were performed. To accomplish this, animals were sedated (diazepam, 200mg-PO, 
Barr Laboratories, Pomona, NY) and echocardiography performed (GE Vivid E9 
Dimension Ultrasound System: M5S 1.5-4.6 MHz active matrix array sector transducer 
probe) in order to measure LV volumes, left atrial (LA) area, posterior LV free wall 
thickness, and ejection fraction. In addition, mitral valve inflow velocities and tissue 
Doppler were used to compute an estimate of pulmonary capillary wedge pressure. 
Digital loops of the two-dimensional echocardiography for the LV long and mid-papillary 
short axis (acquired at 40 Hz) were digitally acquired for analysis (EchoPac, Vingmed, 
General Electric).  
 
5.2.7. TISSUE ANALYSIS 
28 days post-IR and after echocardiography, pigs were anesthetized (5% 
isoflurane) and the LV region containing the MI and remote tissue (LV posterior wall 
encompassing the posterior descending artery) were harvested. LV sections were then 
subjected to histochemical staining for MI size. Briefly, 0.25 cm thick sections of the 
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myocardium were immersed in triphenyl tetrazolium chloride (TTC) solution for 20 min. 
Sections were imaged and quantified using ImageJ. Tissue was also stained for collagen 
content using a picosirius red staining kit. Sections from the MI region were taken for 
subsequent RNA isolation (RNALater, Qiagen). An additional group of pigs (n=6) of 
identical age and weight were included in this terminal study protocol in order to obtain 
referent normal LV myocardium for comparative analysis. 
RNA was extracted from the LV samples (RNeasy Fibrous Tissue Mini Kit, Qiagen) 
and the quality and quantity of the extracted RNA determined (Experion Automated 
Electrophoresis System; Bio-Rad Laboratories, Hercules, CA). The RNA was reverse 
transcribed (iScript cDNA Synthesis Kit; Bio-Rad, Hercules, CA), and pig specific 
primer/probe arrays for apoptosis and inflammation (RT2 Profiler PCR Custom Array, 
PASS-0122 and CAPS11182, respectively, Qiagen) were completed. The reaction was 
performed (RT2 SYBR Green@qPCR Mastermix, Qiagen) and quantified by real time 
(CFX96 real-time PCR detection system, Bio-Rad, Hercules, CA).  The real time PCR 
fluorescence signal was converted to cycle times (Ct) normalized to GAPDH (ΔCt 
method). All PCR assays were performed in duplicate.  
 
5.2.8. STATISTICAL ANALYSIS 
Injection force (n=3), SD-7300 release (n=4), and MMP activity (n=4) are 
presented as mean and standard deviations. For functional studies, pigs were separated 
into three treatment groups, MI (n=8), MI/Gel (n=4), and MI/Gel/SD7300 (n=7). 
Functional data is reported as mean and standard error of the mean. Significance was 
determined using a two-way ANOVA followed by pair-wise comparisons using the least 
significant difference post hoc study. For change from baseline data, a t-test was 
performed using a null hypothesis of a zero mean value. For MI size, PCR, and collagen 
staining data, a one-way ANOVA was performed and pairwise comparisons were 
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performed by an adjusted t-test. All analyses were performed with SPSS software 
(version 24.0, SPSS Inc) and a p-value of < 0.05 was considered statistically significant.  
 
5.3. RESULTS AND DISCUSSION 
This study showcases a biomaterials approach to localize the delivery of a small 
molecule MMP inhibitor. The development of MMP inhibitors for a variety of conditions 
has been hampered by the induction of musculoskeletal syndrome as a result of off-
target action when the inhibitor is delivered systemically. 20,21 Thus, while molecules 
such as SD7300 have been shown to be efficacious in their treatment of disease, their 
utility has been limited in cases of MI, due to limited appropriate delivery mechanisms. 
Here, an injectable hydrogel was developed that could be injected into a tissue to locally 
release an MMP inhibitor.  
 
5.3.1. MATERIAL DEVELOPMENT AND CHARACTERIZATION 
Towards the hydrogel design, we build on our previous work in developing shear-
thinning hyaluronic acid (HA) hydrogels, that assemble from non-covalent guest-host 
crosslinks between β-cyclodextrin and adamantane, allowing them to be injectable into 
tissues (Figure 5.1a,b).25,26,32 In addition to adamantane, β-cyclodextrin has been shown 
to have affinity for a wide range of small molecules, and is frequently used in the 
pharmaceutical industry to solubilize and stabilize small molecules.33,34 Thus, we 
engineered an appropriate interaction for SD7300 sustained release where the molecule 




Figure 5.1. Schematic for hydrogel injection and SD-7300 release from guest-host 
hydrogels. (a) Guest-host hydrogels are formed through self-assembly between 
cyclodextrin (red) and adamantane (green) and loaded into syringes as a single 
component. Upon application of shear via the syringe plunger, guest-host bonds 
dissociate and material flows in a fluid-like state. Upon deposition, guest-host bonds 
reassemble and the material behaves as a solid hydrogel. (b) Image of injection of 
guest-host hydrogel onto a dry surface. (c) Cyclodextrin and SD-7300 (blue) interact 
through reversible interactions at the hydrophobic core of cyclodextrin. Hydrogel 
formulations containing excess cyclodextrin moieties relative to adamantane provide 
binding sites for SD-7300. Affinity for the hydrogel backbone controls retention and 
sustained release from the hydrogel over time.  
 
Cyclodextrin modified HA (CD-HA) was synthesized by aminating β-cyclodextrin 
and subsequently coupling this to HA via amidation so that 35% of repeat units on HA 
were modified with CD (Figure 5.2a). Adamantane modified HA (Ad-HA) was 
synthesized via esterification of HA with 1-ademantane acetic acid so that 25% of repeat 
units on HA were modified with adamantane (Figure 5.2b). Hydrogels were rapidly 
formed through the simple mixing of solutions of purified CD-HA and Ad-HA dissolved in 
PBS.  We have previously shown that these materials possess unique mechanical 
properties that allow for shear-thinning and self-assembly.32 Furthermore, these 
hydrogels possess tunable mechanics based on the relative modification of HA 
Cyclodextrin Adamantane SD-7300 Hydrogel 
Self-Assembled gel in syringe 
Shear-thinning and  
flow during injection 





macromers and injection into the myocardium can indeed provide functional benefits due 
to tissue bulking effects.26 Finally, we have previously used this hydrogel system for cell 
and drug delivery. 24,33 
 
Figure 5.2. 1H NMR spectra for modified hyaluronic acid. (a) NMR spectra for 35% 
functionalized CD-HA and (b) NMR spectra for 25% functionalized Ad-HA.  
 
Towards the design of hydrogels for clinical application, various features are 
important, including injectability and controlled release.  A variety of parameters can be 
modulated to alter such properties and here, we explored the tuning of the ratio of 
CD:Ad groups (1:1, 2:1, 3:1) in hydrogels with the same polymer concentration (6 wt%). 
We observed that all hydrogels were viscoelastic and that hydrogels with the 1:1 ratio 
maintained the highest level of mechanical properties (storage modulus) as determined 
by frequency sweeps (Figure 5.3a), while increasing this ratio led to a drop in 
mechanical properties. This is likely due to the mis-match in the guest-host groups, 
which alters the number of effective crosslinks within the network.  To probe the shear-
thinning behavior of the hydrogels, we conducted a shear rate sweep. Increasing the 
CD:Ad ratio led to a more rapid decrease in viscosity in response to shear, suggesting 
better shear-thinning behavior (Figure 5.3b). The greater mis-match in the guest-host 

















Because a formulation with a balance of mechanical properties for stability and 
shear-thinning behavior for injectability is necessary, as well as an excess of 
cyclodextrin to bind to encapsulated drugs, we selected the 2:1 formulation to proceed 
with future studies. To directly evaluate injectability, we measured the injection force of 
the 2:1 formulation under several different flow rates from a 1 mL syringe through a 21G 
needle. We observed low injection forces across these injection rates (<50N)(Figure 5.3 
c), which are comparable to clinically used hyaluronic acid dermal fillers.35  
 
Figure 5.3. Mechanical testing of various guest-host hydrogel formulations. (a) 
Representative frequency sweeps (conducted at 1% strain between 0.01 Hz and 100 Hz 
using a cone and plate geometry) of guest-host hydrogel formulations containing 1:1, 
2:1, and 3:1 molar ratios of cyclodextrin to adamantane. Increasing cyclodextrin to 
adamantane ratio corresponded to a decrease in mechanical properties for these 
formulations. (b) Continuous flow studies (conducted between 1 and 10 Hz) of 
representative samples of various guest-host hydrogel formulations.  All materials 
displayed shear-thinning behavior, with more rapid shear-thinning occurring in 
formulations containing higher cyclodextrin to adamantane ratios. (c) Injection force data 
at various rates of injection for 2:1 guest-host gel formulation. Bars represent average 
and standard deviation of n = 3 separate runs.  





































































Hydrogels formed from the 2:1 formulation were loaded with SD7300 at a final 
concentration of 0.5mg/mL. The SD7300 release was sustained over 3 weeks with a 
decrease in the release rate over time (Figure 5.4a). This sustained release is a result of 
inclusion of the small-molecule binding cyclodextrin in the hydrogel formulation, which 
was presented in excess of adamantane. In addition to directly measuring SD7300 
release, the bioactivity of released SD7300 was measured using an in vitro estimate of 
MMP-2 inhibitory activity (Figure 5.4b). At all time-points during release, we observed 
almost complete inhibition of MMP-2 activity, suggesting that this formulation is highly 
bioactive during the first month of use (Figure 5.4c).  
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Figure 5.4. SD-7300 release from guest-host hydrogels and associated MMP-2 
inhibitory activity. (a) SD7300 release profile from guest-host hydrogels showing 
sustained release for approximately three weeks. (b) Schematic of fluorogenic MMP-2 
activity assay.  A fluorogenic peptide, when cleaved in the presence of MMP-2, 
generates a fluorescent signal. The kinetics of this generation can be correlated with 
MMP activity, and are decreased through MMP inhibition by SD7300. (c) MMP-2 activity 
associated with release time points obtained during SD7300 release study. Activity was 
negligible for all time points during the release assay.  
 
Inclusion of cyclodextrin as a binding component for small molecules was shown to 
be a successful approach for the sustained release of SD7300. Cyclodextrin is 
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frequently used in numerous pharmaceutical formulations and is an FDA GRAS 
molecule, lending translational merit to this approach for materials design. Because of 
the widespread use of cyclodextrin in pharmaceutical formulations, this approach could 
be broadly applicable for a number of small molecules requiring localized delivery in 
broad applications (e.g. chemotherapeutics). The profile of drug release and activity 
appropriately matches the acute phase of MI. Administration of MMP inhibition during 
this time frame has been shown to be successful in providing attenuation of LV 
remodeling, both in systemic and local administration of inhibitors.23,30,36 By inhibiting 
matrix degradation during this early phase, the mechanical strength of the myocardium 
can be maintained, leading to improved ventricular geometry and function. 
 
5.3.3. MI INDUCTION AND LOCAL HYDROGEL INJECTION 
MI was induced in mature Yorkshire pigs using a catheter balloon occlusion of 
the left anterior descending artery for 90 minutes, then removal of the occlusion to allow 
for reperfusion. Animals were returned for injection ~4 days after induction of MI, and 
hydrogels were injected via a minimally invasive epicardial approach. Hydrogels were 
subsequently injected across 9 injections of 100uL in a 3x3 array pattern within the 
infarcted LAD region (Figure 5.5a,b). The injections left small pockets of transparent 
hydrogel spaced throughout the infarcted myocardium.  Heart tissue was explanted after 
injection and imaged using MRI to evaluate the presence of hydrogel within the tissue. 
Sample short-axis and long axis views show the presence of hydrogel within the 
infarcted myocardial wall (Figure 5.5c,d). After 3D reconstruction, we observed that 
these injection sites contain distinct depots of material within the tissue, suggesting 
retention of the material through injection with this method (Figure 5.5e).  
Additionally, we evaluated our material for the ability to localize a small molecule 
to the myocardium. We loaded hydrogels with IR800 as a model small molecule tracker 
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that could be detected using near-IR fluorescence imaging and tracked its release over 
time (Figure 5.6a). Injections were performed post-infarction, and heart tissue was 
explanted and sectioned into 0.25 cm thick sections 48 hours after hydrogel injection 
and imaged using an IVIS transdermal imaging system. We observed localization of 
fluorescent signal to infarcted myocardium, indicating successful localization of payload 
to the areas of injection in the heart (Figure 5.6 b). 
 
Figure 5.5. Injection of 2:1 guest-host hydrogel formulation into porcine 
myocardium. Guest-host hydrogel was injected in a 3x3 array in the infarct region of the 
myocardial wall using an epicardal injection, accessed via a mini-thoracotamy. (b) Image 
of heart after hydrogel injections. (c) MRI long axis view of hydrogel injection sites in 
explanted porcine myocardium immediately after injection. (d) MRI short axis view of 
hydrogel injection sites in explanted porcine myocardium after injection. (e) 3D 
reconstruction of hydrogel injection sites in explanted porcine myocardium.  
 
a b 
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Figure 5.6. Release of near IR dye in vitro and in vivo. (a) In vitro release profiles of 
IR 800 from 2:1 guest-host hydrogels.  IR 800 released over approximately 1 week from 
guest-host hydrogels. (b) Near IR fluorescent imaging of porcine myocardial sections 
showing IR 800 intensity 48 h after injection. IR 800 was localized to the infarcted region 
of the myocardium, suggesting minimal off target delivery of small molecules.  
 
 
Small molecule MMP inhibitors have had limited success clinically in large part due 
to their inability to be administered systemically without off target effects.20-22 Generally, it 
is hypothesized that the broad musculoskeletal syndrome that has come to be 
associated with systemic administration of these drugs is a result of the disruption of 
normal matrix turnover in healthy sites of the body. While steps have been made to 
address this by targeting specific subsets of MMPs through altering molecule design, 
this has largely been inefficient in providing a means to attenuate these off-target 
effects.37 Using near-IR imaging and near-IR payloads, we have shown the ability for our 
materials to localize small molecules to injection sites in the infarcted myocardium. This 





















allows for direct mitigation of off-target toxicity through localization of SD7300 to only the 
diseased areas of the heart.  
 
5.3.4. LV GEOMETRY AND CARDIAC FUNCTION 
After confirmation of successful material and small molecule retention within the 
infarcted myocardium, we explored the ability of SD7300 loaded hydrogels to promote 
functional improvement after delivery. We evaluated three treatment groups, MI with 
saline injections (n=8), MI with delayed hydrogel injections (n=4), and MI with delayed 
SD7300 loaded hydrogel injections (n=7). Animals were evaluated using 
echocardiography at 14 and 28 days after infarction to determine ventricular geometry 
and filling metrics (Figure 5.7).  
 
 
Figure 5.7. Schematic representation of animal model for functional studies. 
Infarction was generated at day 0 using an ischemia-reperfusion injury, followed by a 
return for material injection at day 3-5. Echocardiography was taken at d 14 and d 28, as 
well as histologic and gene array analysis at d 28.  
 
 Treatment with MI/Gel/SD7300 shows significant decrease in left atrial (LA) area, 
pulmonary capillary wedge pressure (PCWP), E/A ratio, and a significant increase in E’ 
at both 14 d and 28 d time points as compared to saline controls, while gel only 
treatment showed no statistical significance, but a trend for improvement in these 
metrics over saline alone (Figure 5.8a-d). These data suggest that that gel./SD7300 
Infarction Injection Outcomes 
•  Echocardiography 





combination treatment provided increased benefit over gel alone treatment and was 
important for improving diastolic function in the heart.  
 
 
Figure 5.8. Indices of filling for longitudinal functional study of SD-7300 loaded 
hydrogels. (a) Left atrial (LA) area, (b) pulmonary capillary wedge pressure (PCWP), (c) 
E/A ratio, a ratio of peak blood flow during early diastole to peak blood flow in late 
diastole and a metric of left ventricular function, and (d) E’ of animal groups treated with 
MI only (blue, n= 8), MI/Gel (red, n =4) and MI/Gel/SD7300 (green, n= 7) at baseline and 
14 and 28 days after MI. At day 14, animals treated with MI/Gel/SD7300 had significantly 
lower LA Areas, lower PCWP, and higher E’ than animals receiving MI alone. At day 28, 
animals treated with MI/Gel/SD7300 had significantly lower LA Areas, lower PCWP, 
lower E/A ratios, and higher E’ than animals receiving MI alone.  Dashed line represents 
the average of baseline values for all animals used in the study.  Statistics were 
determined using two-way ANOVA, with + representing p<0.05 in comparison to MI 
group and # representing p<0.05 in comparison to MI/Gel group. 
 
Analysis of ventricular geometry shows significant increase in ejection fraction at 
14 d and 28 d time points for the MI/Gel/SD7300 treatment as compared to the saline 





















































(Figure 5.9a). Similarly, MI/Gel/SD7300 treatment showed significantly lower LV end 
diastolic and systolic volumes at both 14 and 28 days, with a non-significant trend for a 
decrease over the gel alone therapy (Figure 5.9b,c). Finally, while no significant trends 
were observed in LV pulmonary wedge thickness at end diastole, MI/Gel/SD7300 
provided significantly higher LV septal thicknesses at end diastole as compared to saline 
controls (Figure 5.9d,e). These trends are also reflected in an analysis of these 
parameters’ percent change from baseline values (Figure 5.10). Taken together, these 
data suggest that Gel/SD7300 combination treatment provided increased benefit over 




Figure 5.9. LV Geometry and Function. (a) Ejection fraction (EF), (b) LV end diastolic 
volume (EDV),  (c) LV end systolic volume (ESV), (d) LV pulmonary wall thickness 
(LVPWThd) at end diastole, and (e) LV septal thickness at end diastole (LVSThD) for 
animals treated with MI (blue, n=8), MI/Gel (red, n=4), and MI/Gel/SD7300 (green, n=7) 
at baseline and 14 and 28 days after MI. Animals in the MI/Gel/SD7300 group had 
significantly higher EF, lower LVEDV, lower LVESV, and higher LVSThd at 14 and 28 
days as compared to the MI group. Dashed line represents the average of baseline 
values for all animals used in the study.  Statistics were determined using one-way 
ANOVA, with + representing p<0.05 in comparison to MI group and # representing 







































































Figure 5.10. Percent change in LV Geometry and Function. Percent change in (a) 
ejection fraction (EF), (b) LV end diastolic volume (EDV),  (c) LV end systolic volume 
(ESV), (d) LV pulmonary wall thickness (LVPWThd) at end diastole, and (e) LV septal 
thickness at end diastole (LVSThD) for animals treated with MI (blue, n=8), MI/Gel (red, 
n=4), and MI/Gel/SD7300 (green, n=7) at baseline and 14 and 28 days after MI. Animals 
in the MI/Gel/SD7300 group had significantly lower decreases in EF, lower increases in 
LVEDV, lower increases in LVESV, and higher increases LVSThd at 14 and 28 days as 
compared to the MI group.  Statistics were determined using one-way ANOVA, with + 
representing p<0.05 in comparison to MI group and # representing p<0.05 in comparison 























































































Both the generation of infarction and the timing of biomaterial delivery are important 
factors when considering the design of MI animal models. It is important to consider the 
generation of clinically relevant infarcts when evaluating new potential therapies. In this 
study, we utilized a balloon catheter approach to provide an ischemia/reperfusion injury 
to the myocardium, as opposed to traditional methods of ligation. Importantly, as the 
majority of patients undergoing an infarction will receive intervention to provide 
reperfusion of the infarcted tissue, this model recreates the scenario of reperfused, 
ischemic tissue in the myocardium. Furthermore, Yoshizumi et al provided evidence 
suggesting that the timing of biomaterial delivery after an infarct plays a critical role in 
determining the efficacy of improvement in tissue and functional outcomes.38 It is also 
important to consider timing from a translational standpoint, as biomaterials-based 
interventions would likely not be administered for at least 24 hours or longer after 
diagnostic and logistical considerations. A significant impact of this work lies in the fact 
that these materials have been evaluated in an ischemia-reperfusion model of MI with 
delayed biomaterial injections. Functional data indicates that these materials are 
effective mechanically and bioactively at delayed time points, suggesting their utility in 
clinically relevant infarcts and time frames.  
 
5.3.5. TISSUE ANALYSIS 
 At 28 days, hearts were harvested from animals and frozen for subsequent 
analysis. First, to assess infarct size and expansion, hearts were sectioned into 4 cm 
thick sections and stained with TTC to assess the metabolically active/inactive regions of 
the myocardium (i.e. healthy/infarcted tissue). Analysis of these sections showed that 
gel/SD7300 treatment provided a significant decrease in absolute MI areas, percentage 
MI of total LV area, and percentage MI of area at risk, as well as a generally non-
significant trend for improvement with gel alone treatment (Figure 5.11). These data 
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suggest improved attenuation of infarct expansion by treatment with SD7300, although 
some effect was observed with injection of hydrogel alone.  
 To further probe mechanistic effects of localized inhibitor treatment, we 
conducted PCR arrays assessing cytokines and fibroblast gene profiles in the infarcted 
region of the myocardium (Table 5.1 and Table 5.2). Almost all genes investigated in this 
study were significantly different than healthy referent controls. This indicates the 
significant underlying biological changes that occur in fibroblast and cytokine expression 
after the induction of MI. Looking closer at gene expression related to ECM production, 
we observed non-significant decreases in Col1A1 and Col6A expression in the 
myocardium in animals treated with Gel/SD7300 as compared to gel alone and MI 
controls (Figure 5.12a,b). Furthermore, collagen presence in the myocardium was 
measured using picrosirus red staining, and we observed a significant decrease in 
collagen in animals treated with Gel/SD7300 as compared to gel alone and saline 
controls (Figure 5.12c). Taken together, these data suggest that Gel/SD7300 treatment 
provides direct influence on cellular phenotype and gene expression in the myocardium, 
ultimately contributing to a decreased fibrotic response.  
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Figure 5.11. TTC staining of sectioned myocardium. (a) Infarct area, (b) percentage 
infarct of total LV area, and (c) percentage infarct of area at risk for animals treated with 
MI (blue, n=8), MI/Gel (red, n=4), and MI/Gel/SD7300 (green, n=7) at 28 days. Animals 
treated with MI/Gel/SD7300 had significantly lower infarct size, and percentage infarct of 
LV and area at risk. Statistics were determined using one-way ANOVA, with + 
representing p<0.05 in comparison to MI group and # representing p<0.05 in comparison 



























































































Table 5.1 Cytokine PCR Array Results. A one-way ANOVA test was used to determine 







MI Only n MI/Gel n MI/Gel/ SD7300 n 





















CSF2 0 Detected# 1 Detected# 2 Detected# 1 
IFNG 4 0.13±1.15 4 0.60±1.18 4 3.27±0.24* 2 





IL6 0 Detected# 1 Detected# 2 ND 6 
IL8 1 2.63±0.85* 5 4.39±1.69 3 4.08±1.80 5 
MMP8 1 1.95 1 0.71±0.80 2 1.33 1 





























Table 5.2 Fibroblast PCR Array Results. A one-way ANOVA test was used to 
determine statistical significance against a referent control (RC) (p<0.05, *) or against MI 






MI Only n MI/Gel n MI/Gel/SD7300 n 
ACTA2 5 4.67±1.12* 4 4.42±0.72* 4 3.93±1.23* 6 
CCN2 5 5.23±0.46* 5 4.56±0.62* 4 4.67±0.87* 6 
COL1A1 5 7.36±0.26* 5 7.02±0.73* 4 6.24±1.11* 6 
COL6A 4 4.11±0.90* 5 3.71±1.07* 4 1.40±1.89 6 
EDA FN 4 8.76±1.36* 6 7.76±0.92* 4 7.74±1.04* 6 
ITGA3 3 4.28±1.17* 5 4.58±0.88* 4 3.58±0.91* 5 
LOX 4 5.20±0.99* 6 5.64±0.49* 4 5.08±1.08* 6 
MYH14 5 0.81±0.47* 6 1.08±0.27* 4 0.77±0.34 6 
P311 4 2.71±0.46* 5 2.92±0.66* 4 2.55±0.81* 6 
SPP1 4 7.61±1.49* 6 6.18±1.52* 4 6.28±1.16* 6 
TGFB 5 3.93±0.70* 6 3.48±0.61* 4 3.12±0.81* 6 









Figure 5.12. Collagen PCR and picrosirius red staining. PCR gene array samples for 
(a) Col6A and (b) Col1A1 and percentage of infarct containing collagen determined 
through picrosirius red staining for animals treated with MI (blue, n=8), MI/Gel (red, n=4), 
and MI/Gel/SD7300 (green, n=7) at 28 days. Animals treated with MI/Gel/SD7300 had a 
trend for lower Col6A and Col1A1 gene expression that was carried forward to 
significantly lower collagen percentages in the infarct. Statistics were determined using 
one-way ANOVA, with + representing p<0.05 in comparison to MI group and # 





































































 This study has shown the development of an injectable, self-assembled hydrogel 
formulation for the delivery of the small molecule MMP inhibitor SD-7300. These 
materials provided month-long sustained release and activity of SD-7300 in vitro, and 
were able to localize small molecules to the myocardium in vivo. Hydrogels delivering 
SD-7300 were delivered in an ischemia-reperfusion, delayed injection model of MI and 
provided improved functional and structural benefit over hydrogel alone and saline 
controls. Finally, we observed that mechanistically, these systems may be exerting their 
effect on collagen production and regulation in the myocardium. Moving forward, these 
materials have broad impact on MMP inhibition therapies, as they solve key problems 
associated with systemic administration of these pharmacologics through local and 
sustained delivery.  
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INJECTABLE GRANULAR HYDROGELS WITH MULTIFUNCTIONAL PROPERTIES 
FOR BIOMEDICAL APPLICATIONS 
 
Adapted from: 
Mealy JE, Chung JJ, Jeong HH, Issadore D, Lee D, Atluri P, Burdick JA. Injectable 
Granular Hydrogels with Multifunctional Properties for Biomedical Applications. 




Biomaterials are being developed as useful therapeutic modalities for a wide 
range of applications, including for the delivery of cells and molecules (e.g. 
pharmacologics, cytokines, growth factors), as cell scaffolds for tissue engineering and 
regenerative medicine, and for mechanical support and tissue bulking.1,2 Many biological 
contexts such as development, inflammation, and tissue repair are quite complex and 
would benefit from multiplexed functionality (e.g. multiple independent drug delivery 
rates, multi-modal degradation behavior, hierarchical mechanical properties) in 
therapeutic design.  
To address this, biomaterials are now evolving beyond simple static and uniform 
materials to incorporate and harness this complexity through advanced material design. 
As examples, approaches to introduce multiplexed functionality in molecule delivery 
have included composite embedding techniques, layer by layer design, or simple co-
encapsulation of multiple factors within a single material.3-6 Furthermore, techniques 
such as photolithography and 3D printing are emerging to improve the spatial design of 
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multifunctional materials.7,8 Despite these advances, there is a disparity between 
creating highly complex materials and doing so in a manner that is broadly amenable to 
clinical translation, such as with the use of injectable materials.   
Injectable materials – commonly hydrogels - can be introduced into tissues via 
percutaneous procedures using syringes and catheters and have been used in 
numerous biomedical applications.9-14 Traditionally, these materials are isotropic and 
homogeneous, frequently designed with a single set of input parameters governing the 
material function. Self-assembled hydrogels are a subset of these materials, where 
crosslinking chemistry is derived from non-covalent interactions including hydrophobic, 
ionic, and guest-host binding.15 These materials are often both shear-thinning and self-
healing, which permits ease of injection and then stabilization upon reaching the 
injection site.  For example, we developed a hydrogel system based on the guest-host 
assembly of polymers modified with cyclodextrin and adamantane that exhibited these 
properties and could be injected into tissues.16-18 Thus, there is a need for materials that 
are injectable and can be engineered to meet the complex demands of tissue repair.   
To meet this challenge, we developed a granular hydrogel system, based on the 
interactions of modular microgel components via guest-host interactions. Particulate 
assemblies are commonly designed through the association of nano- and micro-scale 
components and have recently found utility as cell culture platforms, wound healing aids, 
and drug delivery systems.4,19-22 Guest-host interactions have not been previously used 
for the formation of granular systems and our design provides a high level of control over 
the hydrogel properties through the combination of microgels, including controlled drug 
delivery and porosity for cell invasion.  Specifically, we fabricated crosslinked hyaluronic 
acid (HA) microgels with modular intra-particle covalent crosslinking that were formed 
into an injectable granular hydrogel through the use of cyclodextrin and adamantane 
guest-host inter-particle crosslinking. Here, we explored these materials for application in 
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the treatment of cardiac tissue after injuring, by introducing temporally controlled porosity 
and drug delivery. 
 
6.2. METHODS 
6.2.1. MATERIAL SYNTHESIS  
All materials were purchased from Sigma unless otherwise noted. Sodium 
hyaluronate (HA, 75 kDa, Lifecore) was first converted to a tetrabutylammonium salt 
(HA-TBA) through the use of an ion exchange resin (Dowex50Wx4) to facilitate further 
modification. Briefly, HA was dissolved in aqueous solution and mixed with resin for 4 h, 
after which the resulting solution was neutralized with tetrabutylammonium hydroxide. 
The resulting aqueous solution was frozen and lyophilized to yield dried HA-TBA.  1H-
NMR (360 MHz, Bruker) was used to characterize the final product.  
CD-HA was synthesized using previously described protocols.17 Briefly, an 
aminated β-cyclodextrin was coupled to HA-TBA in a solution of dimethyl sulfoxide 
(DMSO) containing (benzotriazol-1-ylozy)tris(dimethylamino)phosphonium catalyst and 
allowed to proceed for 3h at room temperature. The resulting macromer was purified 
through precipitation in cold acetone, followed by dialysis against water for 2 weeks. The 
CD-HA solution was then frozen, lyophilized, and characterized via 1H-NMR to yield 
~25% modified CD-HA (Figure 6.1a).  
Ad-NorHA was synthesized using a one-pot esterification reaction. HA-TBA, 1-
adamantane acetic acid (TCI America) and 5-norbornene-2-carboxylic acid were 
dissolved in DMSO containing 4-methylaminopyridine and di-tertbutyl dicarbonate 
catalysts. The reaction was allowed to proceed for 20 h at 45 °C. The resulting product 
was purified via precipitation in cold acetone, and dialysis against water for two weeks. 
Ad-NorHA was then frozen, lyophilized, and characterized via 1H-NMR to yield ~40% 
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norbornene and ~40% adamantane modified HA (Figure 6.1b). NorHA was synthesized 
in a similar protocol, excluding the adamantane reactants, to yield ~35% norbornene 
modified HA (Figure 6.1c). 23 
 
Figure 6.1. NMR spectra for modified HA macromers. 1H-NMR (360MHz, D2O) of 
modified hyaluronic acid polymers. (a) NMR spectrum for CD-HA with peaks from δ ~ 
1.35 – 1.85 ppm used for determination of relative modification of cyclodextrin. (b) NMR 
spectrum for AdNorHA with peaks at δ ~ 6.3 ppm and δ ~ 6.0 ppm used for 
determination of relative modification of norbornene and peaks at δ ~ 1.6 ppm and δ ~ 
1.4 ppm used for determination of relative modification of adamantane. (c) NMR 
spectrum for NorHA with integrated peaks at δ ~ 6.3 ppm and δ ~ 6.0 ppm used for 
determination of relative modification of norbornene.   
 
6.2.2. PEPTIDE SYNTHESIS  
Peptides were synthesized via fluorenylmethyloxycarbonyl (FMOC) solid phase 
peptide synthesis and glycanol 2-chlorotrityl substrate (GCKK-RHO, 
GCNSVPMSMRGGSNCG) or a 1,6 diaminohexane trityl resin (GCKK-FITC). Peptides 
were cleaved from the resin in a mixture of trifluoroacetic acid, triisopropylsilane, and 





then dissolved in water, frozen, and lyophilized. Peptides were then characterized via 
MALDI-TOF spectroscopy (Multiflex, Bruker).  
 
6.2.3. DEVICE MANUFACTURE 
As described previously, a three-dimensional monolithic elastomer device (3D 
MED) was used for scale-up of liquid droplets.24 A 3D MED was fabricated with poly 
dimethyl siloxane using a double-sided imprinting method with a hard and soft master. 
The fabrication of hard and soft master was formed by conventional photo- and soft-
lithography. 
  
6.2.4. MICROGEL SYNTHESIS  
A dispersed phase consisting of 3 wt% aqueous macromer (Ad-NorHA, NorHA) 
0.05 wt% I2959, thiol crosslinker, and payload (FITC-BSA, 70kDa RHO-Dextran) 
pumped at 0.6 mL/h was focused into droplets using a dispersed phase of hexadecane 
containing 2 wt% Span80 flowed at 3.5 mL/h. Thiolated crosslinkers were included to 
consume 15% of norbornene units in the case of stable (DTT) and to consume 7.5% of 
norbornene groups in the case of cleavable microgels (GCNSVPMSMRGGSNCG), due 
to increased solution viscosity caused by charge interactions from the peptide. Droplets 
were collected and cured off chip using 365 nm UV light (Omnicure S1500, Excelitas 
Technologies) at approximately 10mW cm-2.  
For covalently-labeled materials, thiolated fluorophores (GCKK-FITC and GCKK-
RHO) were included in the dispersed phase and coupled to microgels via thiol-
norbornene photochemistry during curing. Crosslinked microgels were then purified by 
precipitation in cold acetone, followed by washing with isopropyl alcohol, then 
subsequent drying under vacuum to yield dried microgel product. Microgels were 
characterized using fluorescent and confocal microscopy, and microgel size was 
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calculated using ImageJ particle tracker on an analysis of ~50 microgels. To prepare 
granular hydrogels, microgels and CD-HA were dissolved at 10 wt% in phosphate 
buffered saline.  For mixed microgels, the dried microgel powders were mixed prior to 
hydration. 
 
6.2.5. IN VITRO MATERIAL CHARACTERIZATION 
Granular hydrogels were imaged using a Leica TCSP5 confocal microscope and 
3D reconstructions were rendered using ImageJ. Hydrogel mechanics were assessed 
using a stress-controlled rheometer (AR2000, TA) fitted with a 20 mm diameter flat plate 
geometry and a 300 µm gap height. Oscillatory frequency sweeps were conducted 
ranging from 0.01 to 100 Hz, while cyclic strain experiments were conducted by cycling 
between 1% and 500% strain at 1 Hz. Drug release was assessed using custom 
designed erosion cells in which 30 µL of gel was placed in a 4.3 mm diameter 
depression in a 1.6 cm diameter supernatant chamber. The chamber was filled with 1 
mL PBS supplemented with 1 mM CaCl2 containing either 200 U/mL Type IV 
collagenase or 0 U/mL collagenase. Releaseate was collected and analyzed for FITC-
BSA release at λex = 490, λem = 525 or for RHO-Dextran release at λex = 544, λem = 576. 
Material degradation was assessed using a colorimetric uronic acid assay, as performed 
previously.[18] 
 
6.2.6. IN VIVO MYOCARDIAL INFARCTION STUDIES OF MATERIAL 
DEGRADATION 
The in vivo studies included an infarction and non-infarcted group to investigate 
differential degradation patterns under these two conditions. Using an established 
protocol of myocardial infarction (MI) in a rat model, 8-9 week old male Wistar rats were 
anesthetized, mechanically ventilated and underwent permanent ligation of the left 
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anterior descending artery to produce a 30-40% infarction of the left ventricle, confirmed 
by blanching of the myocardium in the appropriate distribution. Using a 27 G needle on a 
0.5 mL syringe, labeled granular hydrogel containing equal masses of cleavable and 
stable microgels was delivered directly into the infarcted myocardium, as five discrete 10 
µL injections. Care was taken to avoid intraventricular delivery of the hydrogel and the 
formation of visible hydrogel pockets confirmed containment within the myocardial 
tissue. The no MI group received the same 5 x 10 µL injections of gel into healthy 
myocardium corresponding to the infarcted region of the MI group. Due to the nature of 
the procedure, the surgeon was not blinded, although the treatment groups were 
randomly assigned. At pre-assigned timepoints of 1, 2, and 3 weeks, the rats were 
sacrificed and the hearts were explanted, flushed with PBS and preserved in OCT at -
80°C for histologic analysis. 10 µm transverse sections were taken through the area of 
infarct. Sections were stained using hematoxylin and eosin (Sigma) and DAPI (Thermo 
Fisher) staining. Sections were stained using DAPI and hematoxylin and eosin staining.  
  
6.2.7. IMAGE ANALYSIS FROM IN VIVO DEGRADATION STUDIES 
Hearts from MI and non-MI groups (n=3) after 2 weeks were sectioned and three 
sections per animal were analyzed. Injection site area was estimated by the minimum 
region including all microgels (Figure 6.2a). For each section, red and green channel 
images were split (Figure 6.2b) and thresholded with a minimum intensity of 20 and 
maximum intensity of 255 to form a binary mask (Figure 6.2c). Masked areas were 
computed using the “measure” function in ImageJ. Areas of cleavable and stable 
microgels were then normalized to the total injection site area, to yield an area fraction: 𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑 𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙 𝐴𝑟𝑒𝑎= T𝑜𝑡𝑎𝑙 𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙 𝐴𝑟𝑒𝑎/𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑆𝑖𝑡𝑒 𝐴𝑟𝑒𝑎 
Intensity density was calculated by summing the total pixel intensity in either the red or 
green channel, then dividing by the estimated injection site area: 
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𝑁𝑜𝑟𝑚𝑎𝑙𝑖𝑧𝑒𝑑  𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙  𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒 =   𝑇𝑜𝑡𝑎𝑙  𝑀𝑖𝑐𝑟𝑜𝑔𝑒𝑙  𝐹𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑐𝑒𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛  𝑆𝑖𝑡𝑒  𝐴𝑟𝑒𝑎  
Area fractions and intensity densities for each animal were determined, then averaged 
for three biological replicates in each group.  
 
Figure 6.2. Example image series from image analysis on in vivo studies. (a) 
Composite image showing cleavable microgels (green), stable microgels (red), and cell 
nuclei (blue), and the estimated injection site area (yellow). (b) Red channel image of 
stable microgels. (c) Thresholded mask of (b) used for computing stable microgel areas 
used in area fraction calculations. 
 
6.2.8. IN VIVO FUNCTIONAL STUDIES 
 To investigate the potential of the granular hydrogel for the delivery of therapeutic 
molecules, stromal-derived factor 1-alpha (SDF-1α) was encapsulated into the cleavable 
microgel portion of the injectable hydrogel.  Encapsulation was performed as above, 
using DTT as the crosslinker.  The release of SDF-1α from the hydrogel composite was 
investigated as described above, using an ELISA for SDF-1α to quantify release over 
time. 
Using the previously described protocol, MI was generated in Wistar rats via 
ligation of the left anterior descending artery accessed using a left lateral thoracotomy. 
Animals were randomly assigned to three groups: PBS injections, granular hydrogels 
without SDF-1α, and granular hydrogels containing SDF-1α encapsulated in cleavable 
particles at approximately 0.33 µg/mg HA. Similar to degradation studies, materials were 
injected into the border zone region through 5x10 µL, with a final SDF-1α content of 
a b c 
Injection Site Area 
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approximately 1 µg per animal. Prior to tissue explant at 4 weeks, cardiac function was 
determined using a 12-mm pressure-volume loop catheter (Millar).  
 
6.2.9. IMMUNOHISTOCHEMISTRY  
 Using a cryostat, 10 µm tissue sections were obtained from explanted hearts that 
had been washed in PBS, and frozen in OCT. For analysis of microvasculature, tissues 
were stained with primary antibodies for isolectin, α-smooth muscle actin (α-SMA-
AF594, Abcam, 1:400), wheat germ agglutinin (WGA-AF647, 1:300), and DAPI (D1306 
ThermoFisher Scientific, 1:1000).  Images were collected using a Leica DM5000b 
fluorescent microscope with a DFC350 FX monochrome camera at 10x magnification. 
Isolectin area and isolectin co-localized α-SMA area were quantified using ImageJ. At 
least two images collected at the border zone were analyzed and averaged for each 
biological replicate (n=3 for PBS, gel, and gel/SDF groups).  
To determine the effect of granular systems on macrophage response, tissue 
sections were stained for CD68 (MCA341GA, Bio-Rad, 1:300) and with goat anti-mouse 
AF647 secondary antibody (ab150115, Abcam, 1:300) as well as DAPI to visualize 
cellularization. Image analysis of CD68+ area fraction was conducted in ROIs at the 
border zone, in the vicinity of (but not including) microgel injections, determined by the 
absence of significant DAPI staining. Images were thresholded to form a binary mask, 
which was used to determine CD68+ area for at least 4 images per biological replicate 
(n=3 for each group). Finally, to determine the effect of SDF, cells were stained for the 
SDF receptor, CXCR4 using with a goat anti-CXCR4 primary antibody (ab1670, Abcam, 
1:300) and a FITC donkey anti-goat secondary antibody (Abcam 7121, 1:1000). Images 
were thresholded to form a binary mask, over which particle counts were conducted to 
determine CXCR4+ cells for each high powered field.  At least four images were 
analyzed and averaged for each biological replicate.  
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6.2.10. STATISTICAL ANALYSIS 
Data is presented as mean ± standard deviation. Statistical analysis was 
conducted using ANOVA and a post hoc Tukey’s Honestly Significant Difference test 
(p<0.05, p<0.005) on mechanical time sweeps, and a two-tailed student t-test on 
quantified tissue section data (p<0.05). 
 
6.3. RESULTS AND DISCUSSION 
 A granular hydrogel system was developed that involved crosslinked hyaluronic 
acid (HA) microgels with modular intra-particle covalent crosslinking that were formed 
into an injectable granular hydrogel through the use of cyclodextrin and adamantane 
guest-host inter-particle crosslinking (Figure 6.3a). These materials were evaluated for 
modular, multiplexed functionality in vitro and in vivo, and then applied as a therapeutic 
system in a rat model of MI.  
 
6.3.1. MICROGEL AND GRANULAR HYDROGEL FABRICATION 
To fabricate microgels, we used a novel poly dimethyl siloxane (PDMS) 
microdevice to provide high throughput droplet generation (Figure 6.3b).24 Droplets 
contained norbornene modified hyaluronic acid (Figure 6.3a) or adamantane and 
norbornene modified hyaluronic acid (AdNor-HA, Figure 6.3a), di-thiol crosslinkers (e.g., 
dithiotritiol (DTT), peptides), and a photoinitator, as well as fluorescein isothiocyanate 
(FITC) labeled bovine serum albumin (BSA) to image microgels.  The droplets were 
crosslinked using a photoinitiated thiol-ene reaction to form microgels having diameters 
of 43 ± 10µm and 46 ± 12µm, depending on the crosslinker used (Figure 6.4). While 
some size dispersity was observed, potentially due to the drying and hydration process, 
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we were able to manufacture droplets at 0.6 mL of hydrogel precursor per hour through 
the use of 8 parallel droplet generators on a single device. This enabling technology is 
particularly useful when considering scale up of such systems for translation and this 
design has used up to hundreds of parallel droplet generators on a single device, 
processing solutions at rates as high as 1.5 L/h.24  
 In order to form and visualize the material microstructure, dry FITC-BSA loaded 
microgels were reconstituted in phosphate buffered saline (PBS) and combined with 
rhodamine (RHO) labeled cyclodextrin modified HA (CD-HA, Figure 6.3c). Gelation 
occurred instantly upon mixing of these two components to form the granular hydrogel. 
Confocal imaging of the hydrogel showed a clear “brick and mortar” structure, where 
distinct regions of FITC labeled microgels were interconnected by a web of RHO labeled 
CD-HA (Figure 6.3c). These images highlight the hierarchical structure of the material, 
which can be exploited to introduce functionality.   
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Figure 6.3. Guest-host granular hydrogel fabrication. (a) Schematic representation of 
guest-host granular hydrogel formation via the mixing of crosslinked adamantane 
(green) and norbornene (blue) modified hyaluronic acid (AdNor-HA) microgels and 
cyclodextrin (red) modified HA (CD-HA). (b) Schematic representation of the microgel 
fabrication process by which macromer droplets (containing AdNor-HA, di-thiol 
crosslinker, photoinitiator) are formed using a high throughput microfluidic device and 
stabilized through a photoinitiated thiol-ene reaction to form stable microgels that 
averaged ~43 µm in diameter. Scale bars from left to right are 500, 100, and 100 µm. (c) 
Confocal image (cross-sectional (left) and top (right) views) of a guest-host granular 
hydrogel formed with rhodamine labeled CD-HA and fluorescein labeled microgels. 





Figure 6.4. Size distributions of hydrated microgels. Sizing was assessed through 
fluorescent imaging for (A) microgels crosslinked using DTT (n=55) and (B) microgels 
crosslinked using an MMP cleavable peptide (n=49).  
 
6.3.2. GRANULAR HYDROGEL MECHANICAL PROPERTIES 
 The mechanical properties of granular guest-host hydrogels were investigated 
using stress controlled shear oscillatory rheology. A series of three formulations was 
investigated: a “granular hydrogel” group containing 5wt% AdNorHA microgels 
crosslinked with DTT and mixed with 5wt% CD-HA, a “microgel control” group containing 
5wt% NorHA microgels crosslinked with DTT and mixed with 5wt% CD-HA (i.e. no 
adamantane guest for inter-particle crosslinking), and a “polymer control” group 
containing 5wt% AdNorHA microgels crosslinked with DTT and mixed with 5wt% HA (i.e. 
no cyclodextrin host for inter-particle crosslinking) (Figure 6.5a). Across frequencies 
ranging from 0.01 Hz to 100 Hz, the granular hydrogel group maintained the highest 
mechanics of all three groups, with the microgel control group having an intermediate 
level of mechanics, and the polymer control group having the lowest mechanics (Figure 
6.5b). Furthermore, when 1 Hz and 10 Hz frequencies were probed in time sweeps, the 
granular hydrogel was significantly higher (p<0.05) than either control system in both 
storage and loss moduli. All groups, however, did behave rheologically as hydrogels (i.e. 
G’ > G”), potentially as a result of dense microgel packing in all conditions (Figure 6.5c). 
It is likely that the high mechanical properties observed in the granular hydrogel system 
43 ± 10 µm 46 ± 12 µm a b 
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are a result of the guest-host inter-particle crosslinking, while the intermediate 
mechanics in the microgel control could be a result of promiscuous interactions between 
cyclodextrin and unreacted norbornenes, as well as molecule hydrophobicity.25  
 
Figure 6.5. Rheological properties of guest-host granular hydrogels. (a) Schematic, 
(b) frequency sweeps and (c) average storage (G’) and (G’’) across a range of 
frequencies for granular hydrogels (red), microgel controls where cyclodextrin is omitted 
(blue), and polymer controls where the adamantane is omitted (black). Statistical 
significance was assessed relative to the granular hydrogel for the corresponding 
modulus and frequency with * denoting p < 0.05 and # denoting p < 0.005.  
 
 In previously developed hydrogels, guest-host crosslinking imparted shear-
thinning and self-healing properties rendering them injectable; thus, we investigated the 
granular hydrogel behavior using a series of high (500%) and low (1%) strain cycles to 
simulate the conditions of injection (Figure 6.6a). Granular hydrogels maintained high 
mechanics (G’ ~6 kPa) under low strain conditions and then rapidly adopted fluid-like, 
low mechanics (G’ ~100 Pa) under high strain. After returning to low strain, the hydrogel 



















with similar mechanics (G’ ~6 kPa). This suggests that these materials undergo shear-
thinning and self-healing that makes them amenable for syringe injections.  
This behavior was also observed in strain sweeps where increasing strain 
transitioned the hydrogel from a more elastic solid to more viscous liquid behavior 
(Figure 6.6b).  Interestingly, a peak in the loss modulus was observed for the granular 
hydrogel during yield (~30%) strain. We hypothesize that this is related to a 
rearrangement of microgels as the material transitions towards a more fluid-like state. 
Functionally, these granular hydrogels could be injected via needles as small as 27 G 
(~210 µm inner diameter) into dry or aqueous environments with minimal extravasation 
and without the need for long cure times or other stabilizing reactions (Figure 6.6c).  
 
 
Figure 6.6. Shear-thinning behavior of granular hydrogels. (a) Strain-cycle 
experiment for granular hydrogels, whereby materials are cycled between 1% and 500% 
(shaded) strains. (b) Strain sweep analysis of granular hydrogels, indicating yielding 
behavior at high strains.  (c) Ejection of a guest-host granular hydrogel from a syringe 
through a 27 G needle onto a dry surface. 
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6.3.3. MULTIPLEXED, MULTIFUNCTIONAL PROPERTIES OF GRANULAR 
HYDROGELS 
One advantage to the design of the granular hydrogels is that microgels of 
various compositions (e.g., degradation, release profiles of encapsulated molecules) can 
be included, either as separate formulations or even combined into a single injectable 
system.  Generally, the variable properties of the microgels can be tailored through 
altering the crosslinker chemistry.  To explore this, we altered the di-thiol crosslinker 
used for intra-particle covalent crosslinking to be either non-degradable (DTT), to 
generate microgels that will subsequently be referred to as stable microgels, or matrix 
metalloproteinase (MMP) cleavable through inclusion of a peptide 
(GCNSGGRMSMPVSNCG, Figure 6.7a) that incorporates multiple cysteines to present 
thiols and an MMP-cleavable domain, to generate microgels that will subsequently be 
referred to as cleavable microgels.  
 
Figure 6.7. MALDI-TOF spectroscopy of synthesized peptides. (a) MMP cleavable 
peptide (GCNSVPMSMRGGSNCG) m/z: expected 1601, found 1611. (b) Fluorescein 
peptide (GCKK-FITC) m/z: expected 890, found 935 (corresponding to two Na ion 
complex). (c) Rhodamine peptide (GCKK-RHO) m/z: expected 903, found 904.  
 
Stable or cleavable microgels containing a rhodamine labeled dextran (RHO-
DEX) or FITC-BSA payload, respectively, were formed into single-component granular 
hydrogels and release of the payload and the hydrogel degradation (via uronic acid 
c a b 
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assay) were monitored over two weeks.  Studies were performed either in PBS buffer 
alone or containing 200U/mL collagenase to investigate the microgel response to 
proteases. Single component stable and single component cleavable hydrogels 
appeared as a mosaic of red or green microgels, respectively, when imaged on confocal 
microscopy. Some non-uniformity in microgel fluorescence was observed, likely a result 
of diffusion of the fluorescent materials. Over the course of two weeks, the cleavable 
granular gels released their payload significantly faster in the presence of collagenase 
(Figure 6.8a) and degraded more quickly (Figure 6.8b) when compared to the same 
formulation in buffer alone. Comparatively, the stable formulation maintained similar 
release profiles (Figure 6.8c) and degradation behavior (Figure 6.8d) regardless of 
inclusion of collagenase in the release buffer. These data suggest that the choice of 
microgel crosslinker provides a simple approach to control granular gel response and 






Figure 6.8. Molecule release and degradation of single-component granular 
hydrogels. (a) FITC-BSA release and (b) degradation of granular hydrogels fabricated 
from cleavable microgels with (+) or without (-) 200 U/ml collagenase included in the 
buffer. (c) RHO-DEX release and (d) degradation of granular hydrogels fabricated from 
stable microgels with (+) or without (-) 200 U/ml collagenase included in the buffer. 
Degradation behavior was monitored through uronic acid release (n=3).  Scale bar =100 
µm. 
 
We then sought to investigate more complex hydrogels by combining multiple 
microgels into a single granular hydrogel. The advantage of the mixed microgel system 
is the complexity that is obtained through the design, where features such as controlled 
release of multiple factors and controlled cellular invasion are obtained with a single 
hydrogel. We created a two-component granular hydrogel by mixing equal amounts of 
stable and cleavable microgels containing RHO-DEX and FITC-BSA, respectively.  
Microgels of varied composition were fabricated on separate devices, but potentially 
devices could be generated in the future to simultaneously fabricate and mix microgel 
populations on-chip. Visually, these materials contained distinct red, stable microgels 






When two-component hydrogels were probed for release, an accelerated rate of 
FITC-BSA release was observed in the presence of collagenase, while profiles of RHO-
DEX remained approximately similar either with or without collagenase (Figure 6.9b). 
This result is in agreement with how each of the individual microgels behaved in single-
component systems. Furthermore, material degradation rates in the two-component 
systems in the presence of collagenase fell in between single component stable and 
single component cleavable systems, as expected due to the combination of microgel 
populations (Figure 6.9c). Taken together, these data showed both visually and 
functionally, that two-component systems combined the properties of each of the 
previous single-component systems, suggesting that modular exchange of microgel 
types is a successful means to independently multiplex functionality into these granular 
hydrogels.  Although only two components were investigated here, a higher number of 
microgel compositions could be easily introduced.  Additionally, passive release of 
encapsulated molecules could be minimized with alterations in microgel crosslink density 
or through the incorporation of binding agents between the microgel and entrapped 
molecule.  The specific molecules and release profiles incorporated into the design will 
depend on the biomedical application targeted. 
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Figure 6.9. Molecule release and degradation of multi-component granular 
hydrogels. (a) Confocal image (cross-sectional (left) and top (right) views) of two-
component granular hydrogels containing cleavable microgels with encapsulated FITC-
BSA (green) and stable microgels containing RHO-DEX (red). (b) FITC-BSA and RHO-
DEX release and (c) degradation of two-component granular hydrogels with (+) or 
without (-) 200 U/ml collagenase included in the buffer. Degradation behavior was 
monitored through uronic acid release (n=3).  Scale bar =100 µm. 
 
6.3.4. IN VIVO DEGRADATION AND CELL INVASION OF GRANULAR HYDROGELS 
 Myocardial infarction (MI) involves a complex sequence of tissue level changes, 
including inflammation and elevated protease activity, cell death, and fibrosis.26,27 These 
processes ultimately contribute to expansion of the left ventricle, thinning of the 
myocardial wall, a loss of efficient ventricular mechanics and eventual heart failure.28 
Injectable hydrogels are finding widespread use for the treatment of MI, particularly to 
provide mechanical support or deliver therapeutics (e.g., drugs, cells) to the myocardium 
during the remodeling process to improve outcomes.29,30 Emerging knowledge in this 
field suggests that this manner of intervention can be time and disease dependent, 




therapeutic and mechanical targets.10,31 Multifunctional materials may be able to address 
this cascade of events, through multiplexing properties that facilitate spatiotemporal 
delivery of a variety of drugs and/or the manipulation of appropriate cell infiltration.  
As elevated protease activity is a hallmark of MI, we sought to utilize disease-
state protease levels within MI to investigate a responsive two-component granular 
hydrogel. In order to track these materials without the limitations of using encapsulated 
fluorophores, we covalently labeled MMP-cleavable microgels with a FITC-tagged 
thiolated peptide (GCKK-FITC,) and stable microgels with a RHO-tagged thiolated 
peptide (GCKK-RHO) in situ during the microdevice-based microgel synthesis (Figure 
6.7b,c). Granular hydrogels were then formed containing equal amounts of cleavable 
and stable microgels and injected into the myocardial wall of either healthy rats or rats 
having undergone MI. Animals were serially sacrificed after one, two, or three weeks, at 
which point the hearts were explanted and preserved in optimal cutting temperature 
compound. Cardiac tissue was sectioned and imaged using a confocal microscope 






Figure 6.10. Disease dependent behavior of two-component granular hydrogels. 
Two-component granular hydrogels labeled with FITC for cleavable microgels and 
rhodamine for stable microgels were injected into rat hearts either without myocardial 
infarction (no MI) or with MI. Representative images of microgels and cell nuclei (blue) at 
one, two, and three weeks after injection (scale bar = 500 µm).  
 
 At one week, cleavable microgels in tissue sections were a mixture of spherical 
and degraded morphologies, with the MI group displaying more advanced degradation in 
microgel morphology (Figure 6.10). At two weeks, much of the cleavable material was 
cleared in the MI condition, while large aggregates of partially degraded microgels 
remained in the healthy condition.  Finally, at the three-week time point, there was little 
remaining cleavable material in either condition. Across all conditions, stable microgels 
remained present with spherical, non-degraded morphologies throughout the duration of 
the three-week study.  
Microgel presence was quantified at the two week timepoint, due to stark visual 
differences in microgels at this timepoint, by measuring the fluorescence intensity and 
area of both microgel types and normalizing to the total injection site area, in order to 
provide a metric of material mass and volume in the injection site (Figure 6.11a). 
Cleavable material normalized fluorescence intensity in the MI condition was ~40% of 
the no MI condition and cleavable material normalized area was ~20% of the normalized 
1 week 2 weeks 3 weeks 
 MI 
No MI 
 DAPI Stable Cleavable  
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area in the no MI condition. This indicated preferential degradation of cleavable 
microgels in the MI condition. There were no significant differences in stable microgel 
fluorescence intensity in the no MI condition. Relative to the no MI condition, there was a 
small decrease in the amount of stable normalized microgel area in the MI group, 
possibly indicating increased dispersion of the stable microgels in the tissue after MI, 
likely due to increased cellular invasion as the cleavable microgels were degraded 
(Figure 6.11b).  
 
Figure 6.11. Quantification of microgel degradation in vivo. (a) Quantification of 
remaining microgels at 2 weeks, as (a) fluorescence intensity normalized to the injection 
site area or (b) area of microgel to injection site area (n=3). Statistical significance was 
assessed relative to healthy controls with p < 0.05. 
 
Because proteases are elevated during MI, but still maintain a baseline presence 
in healthy tissue, we would expect that protease degradable microgels would eventually 
degrade in both healthy and MI conditions; however, the rates would be significantly 
different. These data suggest that the elevated MMP activity following an infarction is 
responsible for significantly accelerating the degradation of the protease cleavable 
microgels in the two-component granular hydrogel.  
Further to differences in degradation, these materials facilitated cell infiltration, 
due to their highly porous, dynamic nature and this is in agreement with other results 
found in granular systems.22 Through both DAPI (Figure 6.10) and hematoxylin and 






























































































timepoints; however, accelerated cellularization was observed at earlier time points in 
the MI condition concomitant with the more rapid degradation of the cleavable 
component of the dual-microgel system. For the MI conditions, large, vacated pores that 
we believe are a result of cleavable microspheres degrading were observed as early as 
one week and cellularity then increased with time.  For the no MI condition, less 
cellularization was observed at the early times, but cellularity also increased with time, 
albeit at a slower pace when compared to the MI condition with elevated protease levels. 
In the context of MI, these findings are important as protease activity is a significant 
biological handle to signal disease-dependent material response. Beyond MI, elevated 
MMP activity is a key signal for smart biomaterial approaches during other conditions 




Figure 6.12. Hematoxylin and eosin staining. Hematoxylin and eosin staining of MI 












6.3.5. FUNCTIONAL STUDIES OF GRANULAR HYDROGELS DELIVERING SDF-1α 
As we observed controllable degradation and cellular invasion in these materials 
in response to disease states, we considered that granular hydrogel injection may also 
influence cardiac function. Indeed, it has been observed previously that particle-based 
systems in the myocardium can influence functional outcomes in the myocardium 
through tissue bulking and alteration of the inflammatory response. 32,33 Additionally, 
towards controlling cell type in the myocardium, and providing therapeutic delivery, we 
designed the granular hydrogel system for the delivery of therapeutics; specifically, SDF-
1α was encapsulated into microgels, as SDF-1α has been previously shown to be useful 
in the myocardium as a therapeutic for recruiting stem cells and influencing biological 
outcomes such as vascularization. 34  
SDF-1α was encapsulated in cleavable microgels to provide early, disease 
dependent delivery to recruit stem cells to the infarct. We assayed release of SDF-1α  
using an ELISA kit in the presence of 500 U/mL collagenase, and observed release of 
SDF-1α  over approximately two weeks (Figure 6.13).  This aligned well with the goal of 
early recruitment of cells. Because stable particles themselves have previously shown 
functional benefit in MI models, we formulated a granular system as done previously, 
containing cleavable particles either empty or loaded with SDF-1α, as well as stable 
particles. Wistar rats received infarcts and were treated with either PBS (PBS, n = 15), 
blank granular gels (Gel, n = 7), or granular gels loaded with SDF-1α  (Gel/SDF, n = 7). 
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Figure 6.13. Release of SDF-1α from granular hydrogels. Granular hydrogels of the 
formulation investigated previously loaded with SDF-1α contained in cleavable microgels 
were incubated in the presence of 200 U/mL collagenase as a means to replicate the 
proteolytic infarcted myocardium. Supernatant was sampled and collected over 4 weeks, 
and releaseates were analyzed for SDF-1α content using an ELISA kit.  
 
When investigating the functional outcomes, it was observed that only the 
granular hydrogel delivering SDF-1α  had a significantly improved ejection fraction over 
the PBS control (Figure 6.14a).  Both granular hydrogel groups (with and without SDF-
1α) groups showed significant improvements in cardiac output, as well as dP/dtmax, a 
measure of cardiac contractility as compared to PBS controls (Figure 6.14b,c). 
Surprisingly, the granular hydrogel treatments did not improve volumes after treatment 
(Figure 6.14d,e).  It is likely that both granular materials are influencing the myocardium 
by providing a means of cellular invasion and bulking, as has been demonstrated 
previously with numerous hydrogel systems and one treatment group improved 
outcomes with SDF delivery by altering local cellularity.  



















Figure 6.14 Functional outcomes at 4 weeks after MI. (a) Ejection fraction, (b) cardiac 
output, (c) dp/dtmax, (d) left ventricle end-systolic volume (LVESV), and (e) left ventricle 
end-diastolic volume (LVEDV) for animals treated with PBS (n=15, blue), granular 
hydrogels (gel, n=7, red), or granular hydrogels loaded with SDF (gel/SDF, n=7, green). 
Statistical significance was assessed using a one-way ANOVA with post hoc Tukey 
testing with * representing p<0.05 against PBS control group.  
 
The biological role of particle based material systems in the myocardium has 





































































































acid/PLGA microsphere composites. 32,33 These systems have been shown to stimulate 
the inflammatory response in a unique way to induce beneficial stabilization to the infarct 
through ECM production as well as vasculogenesis, ultimately leading to improved 
outcomes including scar fraction and functional benefits. Particles in these systems fell 
into a unique size regime (>10µm, <100µm) that mitigates fibrous capsule formation, but 
prevents macrophage phagocytosis. Granular hydrogels developed here utilized 
microgels of a similar size regime to microgels. To better understand the biological 
response to the injected granular hydrogels, markers for inflammation, cell receptors, 
and vascularization were investigated using immunohistochemical analysis (Figure 
6.15a).  Analysis of the inflammatory state of the myocardium local to injection sites 
shows that both gel groups and gel/SDF groups have significantly elevated macrophage 
levels as compared to PBS control groups (Figure 6.15b). This is likely a result of the 
granular nature of these materials, as previous studies investigating PLGA microsphere 
implants in the myocardium have shown elevated pro-healing, and overall inflammatory 
response. 33 While elevated inflammatory response is often thought to be detrimental in 
implanted materials, the potential for increased collagen deposition and vascularization 
generating stabilization of the infarcted tissue in the myocardium could provide 
significant benefit in acute phase MI.  
We further explored the biological function of SDF-1α  delivery from granular 
hydrogels. To this end, we stained tissue sections for the presence of CXCR4, the cell 
receptor for SDF that is often present on recruited cells. Gel/SDF treatment groups 
showed significantly higher CXCR4+ cell counts as compared to either PBS or gel 
treatments without SDF, suggesting that SDF delivery was in fact localizing stem cells to 
the myocardium in this system (Figure 6.15c).  
Finally, we evaluated vascularization as a further downstream biological process 
of both macrophage invasion and stem cell recruitment. Areas of colocalized regions 
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staining positive for isolectin and αSMA were quantified. Only the Gel/SDF treatment 
group showed significant increase in this area as compared to PBS controls, indicating 
that SDF was critical to stimulating vasculogenesis in these systems. (Figure 6.15d). In 
summary, it is clear that granular hydrogels provide improved functional benefits to the 
myocardium, play a role in altering macrophage response, and that SDF delivery from 
these systems provides synergistic effect through the recruitment of stem cells to and 




Figure 6.15. Immunohistochemistry for myocardial sections at 4 weeks after MI. (a) 
Representative images of macrophage (CD68, magenta), migratory stem cells (CXCR4, 
green), and vascular (isolectin, green and αSMA, red) staining. All images are co-stained 
with DAPI (blue). Scale bar represents 200µm. (b) CD68+ area fraction, a marker of 
macrophage activity, (c) CXCR4+ cells, a marker of miratory stem cells induced by SDF, 
and (d) isolectin/ αSMA co-stained area, a marker of microvasculature determined in 
regions local to microparticle injections at the border zone of MI. Statistical significance 
was assessed using a one-way ANOVA with post hoc Tukey testing with * representing 



























































































In conclusion, we developed an injectable granular hydrogel, using guest-host 
interactions. This hydrogel displayed shear-thinning and self-healing properties that 
rendered it amenable to injection into dynamic environments and abrogated the need for 
controlled working/cure times that are often associated with other crosslinking 
mechanisms. The granular structure of this material allowed for multiplexing of complex 
release and degradation profiles that could be adjusted through modular exchange of 
intra-particle crosslinking or through combining multiple microgel types. The multiplexed 
material properties and high porosity of two-component granular hydrogels provided for 
unique disease-dependent behavior and high levels of cell invasion after injection into 
myocardial tissues. Finally, these materials were able to deliver the chemokine SDF-1α 
to improve cardiac function and biological outcomes.  
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CONCLUSIONS, LIMITATIONS, AND FUTURE DIRECTIONS 
 
7.1. OVERVIEW 
Work presented in this dissertation shows the development, characterization, and 
application of guest-host (GH) interactions in designing hydrogels with properties that 
are appropriate for biomedical applications. As described in Chapter 3, biomaterial 
systems based on this class of interactions are finding broad use in the fields of drug 
delivery, cell delivery, material implants, and even towards basic science applications.1 
Specifically, hydrogels engineered with GH interactions have been useful in the context 
of myocardial infarction (MI), as outlined in Chapter 1, largely due to their ability to be 
injected into tissues.2-4 Through further engineering, this thesis expands the application 
of GH hydrogels to MI, by incorporating small molecule delivery or through multiplexing 
design where properties such as degradation, delivery, and cell invasion are included in 
a single system.5  
More specifically, Chapter 4 described utilizing the reversible nature of 
cyclodextrin GH chemistry to tune small molecule sustained release for a number of 
model payloads as well as representative small molecule pharmaceuticals.6 Chapter 6 
described the development of granular hydrogels, formed through GH mediated 
assembly of microgel components, that allowed for the modular combination of different 
populations of microgels (each with different material design parameters, e.g. 
degradation, payload, etc) into a single bulk, injectable material with multifunctional 
properties.7 Both of these advances in material design were then applied in models of 
MI. Chapter 5 described the design of GH hydrogels for the sustained release of 
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SD7300, an MMP inhibitor that requires local delivery, and the application of the 
hydrogel system to a porcine model of MI with clinically relevant timing and 
percutaneous delivery. Additionally, work at the end of Chapter 6 outlined the potential 
efficacy of multifunctional granular materials in treatment of MI, with a capacity for 
disease responsive behavior and tunable cell invasion properties. The remainder of this 
chapter will focus on the main conclusions, limitations, and future directions associated 
with each of these aims. 
 
7.2. SPECIFIC AIM 1 
DESIGN AN EASILY INJECTABLE GUEST-HOST HYDROGEL FORMULATION FOR 
SUSTAINED SMALL MOLECULE DELIVERY 
 
7.2.1. CONCLUSIONS 
 In this aim, we were able to demonstrate the ability of cyclodextrin to modify the 
affinity of HA polymers for small molecules through the use of analytical calorimetric 
methods. When assembled into hydrogels through GH interactions, the inclusion of 
cyclodextrin altered the diffusion and bulk release of encapsulated peptides.  We 
determined that these outcomes were tunable based on two key parameters: the level of 
cyclodextrin content in the GH hydrogels and the payload affinity for cyclodextrin. The 
mechanical properties of these materials were not greatly influenced by the 
encapsulation of small molecules, likely due to the higher relative affinity of cyclodextrin 
for adamantane, the interaction driving polymer association in this system. Ultimately, 
we were then able to use these parameters as a means to provide tunable sustained 
release of small molecule antibiotics and chemotherapeutics. This work has expanded 
the capabilities of injectable hydrogel systems to easily incorporate small molecule 
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sustained release, an important class of therapeutics that frequently require carriers 
such as these injectable hydrogels for efficacy. 
 
7.2.2. LIMITATIONS AND FUTURE DIRECTIONS 
 Material systems developed in this chapter lay a foundation for simple strategies 
to provide sustained small molecule release from biomaterials; however, there are 
numerous instances where the findings could be expanded with further material iteration. 
Specifically, the studies were confined to the investigation of one host molecule 
(cyclodextrin) and only a handful of different guest molecules. Thus, the observed scope 
of the effects on sustained release remains somewhat limited. While this selection of 
host molecule was highly useful, due to the GRAS classification of cyclodextrin and its 
general use as a pharmaceutical excipient, it is possible that investigation of other host 
molecules such as cucurbits, etc could provide an even more pronounced effect on 
sustained release.8,9 Furthermore, while we observed no significant effects of molecule 
encapsulation on material mechanics in the system investigated, it is possible that 
through competitive binding, small molecules with high affinity for cyclodextrin (i.e. 
approaching that of adamantane) could alter hydrogel mechanical properties.  
 Towards future studies, one important advance would be modeling to predict 
release profiles for small molecules encapsulated in GH hydrogels. In the case of other 
material systems such as PLGA microspheres, it is often simple to predictively 
generalize release profiles since release is largely controlled by material degradation 
and structure, and is largely independent of the nature of the selected payload.10,11 Our 
experience with these systems is that release is not only controlled by material 
parameters (e.g., concentration, extent of modification), but also the specific interaction 
between material and payload, making it difficult to predictively generalize release 
profiles, although some groups have taken steps towards this in protein-based 
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systems.12 Particularly with cyclodextrins, there is a wealth of molecule affinity data that 
could be directly integrated to a predictive modeling approach, or data that could be 
gathered using modeling software of molecular interactions.13 Within models, variations 
in parameters such as host (cyclodextrin) concentration, guest (adamantane) 
concentration, drug concentration, and drug-host affinity, would be useful to 
quantitatively determine their effect on release in silico to guide the design of GH 
hydrogel formulations for future small molecule release.  
 
7.3. SPECIFIC AIM 2 
RELEASE A SMALL MOLECULE PROTEASE INHIBITOR FROM AN INJECTABLE 
GH HYDROGEL FOR TREATMENT OF MI 
 
7.3.1. CONCLUSIONS 
 In this aim, we were able to design GH hydrogels as easily injectable materials 
for sustained SD-7300 release. First, we screened material formulations to assess 
shear-thinning properties to determine a formulation that balanced shear-thinning for 
injection, mechanical properties for deposition into tissue, and cyclodextrin content for 
SD-7300 retention. We determined a formulation that was easily injectable based on 
injection force testing, and assayed it for SD-7300 release. Hydrogels with encapsulated 
SD-7300 had sustained release over several weeks and showed MMP-2 inhibitory 
activity over this entire period, a timeline that is concurrent with the acute phase of MI. 
When investigated in a porcine MI model of ischemia-reperfusion, GH hydrogels could 
be injected and retained in the myocardial wall and localized small molecules to this 
region Animals received injections 3-5 days after MI of hydrogels containing SD-7300 
with hydrogels or PBS injections alone used as controls. Gel/SD7300 treatment 
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improved functional outcomes such as ejection fraction, as well as histological outcomes 
including MI area and collagen content when compared to hydrogel or PBS injection 
alone. Thus, GH hydrogels were able to successfully sustain the release of SD-7300 to 
provide therapeutic efficacy in a clinically relevant, delayed injection animal model.  
 
7.3.2. LIMITATIONS AND FUTURE DIRECTIONS 
 This study showed the development of GH hydrogels for the sustained release of 
SD-7300, and application in a porcine model of MI. As a pre-clinical model, this study 
was translationally focused, incorporating an ischemia-reperfusion infarct as well as 
delayed injection of hydrogels, both features that represent more common infarct and 
treatment scenarios in patients. This study, however, is not without limitations. This 
study was limited through necessary design choices in both materials and animal 
models. While logistically challenging to complete, a number of dosing studies are 
necessary to optimize both drug dosing and material volumes in the myocardium for 
specific drugs and material formulations. In depth clarification of these parameters will 
help to clarify the interplay between material bulking, and the biological effects targeted 
by therapeutic payloads such as SD-7300. Further developments of catheter/injection 
systems are needed, to provide assurance in the safety of material injection, to limit any 
risk of embolism upon ventricular injection of this material. This could include catheter-
based or helical needle injections to afford surgeons increased control over material 
placement in the myocardial wall. Further, the scope of this project was confined to one 
inhibitor at a 3-day delayed timepoint.  
Both timing of material injections and MMP inhibitor subtype have been shown to 
play a critical role in MI, often with optimal windows for material injection and specific 
MMP inhibition.14-16 Future directions for this work could investigate the inhibitor 
treatment at a range of different injection time-points, to evaluate further efficacy of the 
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therapy. All studies completed here evaluated relatively short (~4 weeks) time points 
after infarct and administration of treatment for structure and function. As the effects of 
these therapies influence the long term progression of heart failure, it is important to 
consider analysis of much longer time points (i.e. months to years) after MI and 
treatment to gain a full understanding of the impact of these systems.  
 
7.4. SPECIFIC AIM 3 
 DEVELOP AN INJECTABLE GRANULAR HYDROGEL SYSTEM FOR TREATMENT 
OF MI  
7.4.1. CONCLUSIONS 
In this aim, we showed the design of granular hydrogel systems that were 
injectable through the incorporation of GH chemistry. Microgels with adamantane 
chemistry were formed using a microfluidic approach that is scalable to high throughput 
production. These particles were assembled using CD-HA into brick and mortar type 
structures that were visualized using confocal microscopy. Furthermore, the mechanical 
properties of these systems were dependent on GH interactions between particles and 
CD-HA polymer incorporated into the system. Granular hydrogels developed in this aim 
were shear-thinning and self-healing, and were injectable through needles as small as 
28 G. Through the design of intra-particle covalent crosslinking chemistry and payload 
encapsulation, particles were designed to encapsulate a range of payloads that released 
under a variety of conditions. These particle populations were combined into a single 
granular hydrogel, which represented the behavior of the specific microgel compositions 
(payload, release profile).  
Multifunctional granular hydrogels were injected into infarcted and healthy 
myocardium in rats, and displayed disease responsive and disease independent 
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behavior in subpopulations of microgels in these systems. Furthermore, the granular 
nature of these materials allowed for high degrees of cell invasion, which is also 
dependent on particle design and disease interaction. Cell-material interactions are 
critical in this context, as cell invasion and the subsequent stimulation of inflammatory 
processes such as collagen deposition and vasculogenesis are beneficial to stabilizing 
the infarcted myocardium. In rat MI studies, we showed that granular systems 
themselves provide functional benefits, likely by influencing macrophage response and 
stabilizing the infarct through this response, as has been seen in previous studies.17 
Furthermore, we controlled cells invading the myocardium, by delivering the chemokine 
SDF-1α from an individual microgel component. Materials loaded with this chemokine 
were able to provide increased recruitment of CXCR4+ cells to the myocardium, and 
showed improved benefit in ejection fraction.  This microgel system provides a platform 
for investigation of numerous therapeutic molecules to treat MI. 
 
7.4.2. LIMITATIONS AND FUTURE DIRECTIONS 
 Materials developed in this aim provided a new avenue for material design by 
multiplexing material properties into a single system with controllable bulk mechanical 
properties for injection. Studies conducted in this aim do have several limitations. Animal 
studies in this aim were conducted in small animal models. While these studies are 
beneficial for throughput and gaining insight into material behavior in an in vivo context, 
there are limitations to testing myocardial injections in small animals. Due to the injected 
volumes of hydrogel in the rat myocardium, it is likely that in addition to the biological 
roles of these systems described in chapter 6, these granular systems are exerting a 
major effect through cardiac bulking. Furthermore, these systems were delivered 
concurrently with the generation of infract, which itself was a permanent ligation of 
cardiac vasculature. These approaches in an animal model are not representative of the 
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conditions these systems would experience in a clinical setting, in terms of both injection 
timing and potential tissue perfusion. Moving towards analysis in large animals can help 
to clarify the interplay between tissue bulking, cell invasion and vasculogenesis, and the 
effect of delivered payloads such as SDF.  
 These studies have also only shown early proof of concept for the use of 
granular systems as drug delivery depots. Due to the ease of combining numerous 
payloads, release rates, and degradation properties, these materials would make an 
excellent platform for complex drug delivery problems involving synergistic release of 
multiple payloads. Prior work has shown the benefits of delivering multiple factors to the 
myocardium associated with vasculogenesis, however, this could be expanded to 
introduce further targets such as cell recruitment and MMP inhibition.18 Furthermore, this 
system lends itself to complex release profiles, which could be useful in timing-critical 
delivery challenges such as in vivo cell reprogramming, a process requiring sequential 
delivery of numerous factors.19  
 A final limitation of this work is that the scope of these materials was confined to 
the design of ~40 µm diameter microgel particles. The role of particle size could be 
investigated in future studies to determine the effect on both material mechanical 
properties, as well as induction of in vivo cell invasion and ECM deposition. Finally, the 
utility of these materials could be further expanded to basic science studies in cell 
culture and mechanobiology. 
 
7.5. OVERALL SUMMARY 
 Overall, broad conclusions of this dissertation relate to the development of novel 
biomaterial function through the utilization of GH chemistry, and the application of these 
materials for myocardial infarction therapies. Through material design, we were able to 
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generate unique hydrogel systems that could deliver small molecules or provide 
combinatorial functionality. These platform systems are broadly compatible with a range 
of molecules for drug delivery, providing future potential investigating translational 
challenges such as the local delivery of small molecules, or more academic pursuits 
clarifying the nature of timing, and synergistic therapies in drug delivery strategies for MI. 
Hydrogel systems for drug delivery have enormous potential as an emerging class of 
therapeutics in the myocardium. As an understanding of the effects of biomaterials in the 
myocardium matures, studies and materials such as the ones of this thesis will form the 
groundwork for translation and solving clinical delivery challenges.   
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